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1 INTRODUCTION 
 
1.1 Gliomas 
1.1.1 Cellular origin of gliomas 
The cellular origin of gliomas is a matter of investigation. Evidence from glioma mouse 
models and human clinical data indicate that gliomas are developing from neural stem cells 
(NSCs), glial progenitor cells or differentiated progeny. The cell of origin has the potential 
to initiate oncogenic mutations that drive gliomagenesis (Modrek et al., 2014). There are 
two working hypothesis postulating that cellular heterogeneity and propagation of gliomas 
is regulated by clonal or cancer stem cell (CSC) model (Reya et al., 2001). The hypothesis 
of clonal growth of cancer postulates that single cancer cell has the ability to proliferate, 
self-renew and acquire genetic mutations, thus creating clonally derived subpopulations 
within the tumor (Schonberg et al., 2014). The CSC model assumes that a population of 
cells in the tumor possesses stem cell-like properties, such as the ability to self-renew, 
differentiate and proliferate. CSCs give rise to the cells that after reaching a fully 
differentiated stage reach limited tumorigenic potential (Schonberg et al., 2014). According 
to both models, the CSC and the clonal model, glioma cells acquire genetic mutations, 
accounting for the cellular and genetic heterogeneity (Modrek et al., 2014).  
Cells having the ability to form gliomas are widely spread throughout the Central Nerves 
System (CNS), mostly developing within the cerebral hemispheres (Zong et al., 2012). 
Some of the glioblastomas occur in the subventricular zone adjacent to the lateral 
ventricles, while others arise in the subcortical white matter (Bohman et al., 2010; Lim et 
al., 2007). Region-specific features of the brain microenvironment and properties of the 
local progenitor population may affect the tumor phenotype (Gibson et al., 2010; Johnson 
et al., 2010). Distinct cells of origin may give rise to the same pathological manifestations, 
but it is also possible that different genetic mutations might transform the same cell into 
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different types of gliomas (Zong et al., 2012). Hence, defining the key driver mutations and 
cell types giving rise to gliomas is a prerequisite to understand the cancers biology, develop 
prevention strategies and effective treatments (Modrek et al., 2014; Zong et al., 2012). 
 
1.1.2 Histopathological and molecular classification of gliomas 
Gliomas are classified based on histopathological features, with reference to their 
association with specific glial lineages (Vigneswaran et al., 2015). The principles of 
histological analysis include findings of nuclear atypia, proliferative activity, microvascular 
proliferation, and necrosis (Louis, 2006). According to the grading of the World Health 
Organization (WHO) malignant gliomas are divided into astrocytic, oligoastrocytic, 
oligodendroglial, and ependymal tumors (Louis et al., 2007). Astrocytomas have 
morphological similarities with normal and reactive astrocytes, and express the astrocytic 
marker GFAP (Rousseau et al., 2006). Oligodendrogliomas are related to cells of the 
oligodendrocyte lineage, specifically oligodendrocyte progenitor cells, which express the 
markers including Olig2, NG2 and PDGFRα (Riemenschneider et al., 2004; Rousseau et 
al., 2006; Shoshan et al., 1999; Zong et al., 2012).  
Malignant astrocytomas are further classified on the basis of tumor grade into less 
aggressive, diffuse astrocytomas, defined as WHO grade II (AII), aggressive, anaplastic 
astrocytomas, defined as WHO grade III (AAIII), and the most aggressive glioblastomas 
(GBMs) defined as WHO grade IV (Fig. 1.1.2-1) (Zong et al., 2012). Among astrocytomas, 
GBMs are the most frequent brain malignancies in adults (Louis et al., 2007). Based on 
clinical presentation GBMs are further classified as primary (pGBM) or secondary (sGBM) 
(Kim et al., 2013). Secondary GBMs are progressing from lower-grade precursor lesions, 
whereas primary GBMs develop de novo and usually at the time of diagnosis present 
advanced tumor features. Secondary GBMs are found in younger patients with median 
diagnosis age of ~45 years and occur less frequently than pGBM, i.e. in ~5% of GBM 
cases. The median age of diagnosis of pGBM patients is ~60 years (Olar and Aldape, 2012; 
Vigneswaran et al., 2015).  
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Due to histopathological similarity, GBMs require an identification of genetic alterations to 
describe their molecular subtypes (Ohgaki et al., 2004; Phillips et al., 2006; Verhaak et al., 
2010). Phenotyping at a genome-wide level expanded the classification of gliomas by 
further dividing morphologically identical tumors into four subtypes, including classical, 
proneural, neural, and mesenchymal tumors (Verhaak et al., 2010; Vigneswaran et al., 
2015; Zong et al., 2012). Secondary GBMs are usually classified as proneural, whereas 
primary GBMs may be of any of the subtypes (Cohen et al., 2013).  
 
 
 
Figure 1.1.2-1. Simplified classification of gliomas based on WHO Classification of Tumors of The 
Central Nervous System (Louis et al., 2007). Classification is based on findings of histopathological 
features of cancer cells, including nuclear atypia, proliferative activity, microvascular proliferation, and 
necrosis. Figure adapted from the WHO Classification of Tumours of The Central Nervous System System 
(Louis et al., 2007). 
 
The new WHO Classification of Tumors of The Central Nervous System (Louis et al., 
2016) introduces molecular and cytogenetic information to assist glioma classification (Fig. 
1.1.2-2). Detection of mutations in isocitrate dehydrogenase (IDH) (Bleeker et al., 2009; 
Parsons et al., 2008) is currently a prerequisite for tumors classification. The wild-type 
IDH1 catalyzes the oxidative decarboxylation of isocitrate to α-ketoglutarate. Whereas the 
mutant protein, with arginine 132 altered to histidine, converts α-ketoglutarate to R(-)-2-
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hydroxyglutarate (Dang et al., 2010; Jin et al., 2011). Accumulation of 2-hydroxyglutarate, 
which acts as an oncometabolite, inactivates oxygenases (histone demethylases and TET 
5’-methylcytosine hydroxylases) and leads to significant modifications in methylation 
profile, length of telomeres and gene expression (Cohen et al., 2013; Garber, 2010). 
Histologic assessment supported by genetic and epigenetic analysis in consequence 
produces more accurate and reproducible diagnostic criteria (Vigneswaran et al., 2015). 
 
 
 
Figure 1.1.2-2. The new WHO Classification of Tumors of The Central Nervous System (2016). In 
contrast to the old grading, the new classification is based not only on histopathological features, but also 
includes IDH status and other genetic alternations. The IDH1 refers to isocitrate dehydrogenase 1, ATRX to 
alpha-thalassemia/mental retardation syndrome X-linked, and NOS to not otherwise specified. Figure adapted 
from the WHO Classification of Tumours of The Central Nervous System (Louis et al., 2016). 
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1.1.3 Microenvironment of glioblastoma 
Solid tumors exist as tightly connected entities depending on their cellular environment. 
Individual cells may adapt to the local environment, but also change the surrounding to 
accommodate their own needs. For this reason, a complex communication involving 
interaction between tumor cells and non-malignant neighboring cells is required 
(Godlewski et al., 2015). GBMs are predominantly composed of cells resembling immature 
glia (Zong et al. 2013). The heterogeneous GBM tissue consists of tumor cells, surrounding 
blood vessels, immune cells, and extracellular matrix. Additionally, its structure includes 
stem cell-like cells and parenchymal cells. Tumor-associated non-neoplastic parenchymal 
cells include vascular cells, microglia, peripheral immune cells, normal astrocytes and 
neural precursor cells that play an essential role in cell-cell communication. The 
vasculature supports GBM cells with nutrients, oxygen and provides a specialized niche for 
stem-cell like cells. Microglia contribute to the tumor mass and support cell invasion. 
Normal astrocytes not only can be transformed into reactive cells under the pressure of the 
environment, but also can secrete a number of factors that alter tumor biology (Fig. 1.1.3-
1). Altogether, cytokines, growth factors, and chemokines released in extracellular vesicles 
(EV) may support tumor initiation, angiogenesis, proliferation, and invasion (Pollard et al., 
2004; D’Asti et al., 2016), thus providing an additional level of complexity and network 
communication (Godlewski et al., 2014). 
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Figure 1.1.3-1. The microenvironment of glioblastoma. Tumor surrounding is composed of specialized cell 
types, which may support tumor growth or invasion. Different cell types from the tumor microenvironment 
communicate both locally and at distant ranges via the release and uptake of EVs. Such communication can 
contribute to tumor progression by transferring bioactive molecules. Figure from Godlewski et al., 2014. 
 
1.1.4 Implications for diagnosis and therapy  
Gliomas characterized by an astrocytic phenotype have a poorer prognosis than 
oligodendroglias of a corresponding grade (Ohgaki et al., 2004). Genetic alterations 
associated with good predictions, such as loss of heterozygosity of 1p19q (Barbashina et 
al., 2005), IDH1 mutation (Yan et al., 2009) and glioma-CpG island methylator phenotype 
(G-CIMP) (Noushmehr et al., 2010) are also more common in oligodendrogliomas and 
sGBMs (Zong et al., 2012). Among gliomas, the most common and lethal CNS tumors are 
GBMs. Despite surgical resection and aggressive treatment the prognosis for GBM patients 
is typically very poor. In the United States, the GBM incidence rate is 3.19/100000 people 
(Thakkar et al., 2014). The mean survival for GBM patient under currently available 
treatment is approximately 14.6 months from the time of diagnosis. The therapy commonly 
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includes surgical resection, radiotherapy and adjuvant temozolomide application (Stupp et 
al., 2005).  
The failure of conventional approaches in curing GBM indicates the need for novel 
therapies, which target the cells of origin (Zong et al., 2012) or residual tumor cells (Wilson 
et al., 2014). Until now, molecule-targeted therapies, including inhibition of growth factor, 
and intracellular signaling pathways provided very limited or no therapeutic benefit. 
Similarly, immunotherapy or gene therapy, including cytotoxic gene therapies, or oncolytic 
viral vectors demonstrated minimal efficacy (Wilson et al., 2014). To understand the 
complex biology of GBMs, a variety of therapeutic approaches were undertaken but despite 
promising results in the preclinical phase, the therapies had limited or no effects in clinical 
trials (Wilson et al., 2014). Therefore, treatment of GBMs remains highly challenging. 
 
1.2 Translational control by CPEBs 
1.2.1 Principles of translation 
Translation of mRNAs is tightly regulated in three major phases: initiation, elongation and 
termination (D’Ambrogio et al., 2013; Groppo and Richter, 2009). Regulation of translation 
efficiency is predominantly controlled at the initiation phase and involves eukaryotic 
translation initiation factors (eIFs) and other auxiliary proteins interacting with eIFs and 
with mRNAs. Initiation factors assemble on the 7-methyl-guanosine (m7GpppG) cap 
structure at the 5′end of RNAs (Sonenberg and Hinnebusch, 2009) and form the eIF4F 
complex. The complex is assembled with eIF4E, a cap binding factor, eIF4G, a scaffold 
protein interacting with eIF4E, eIF4A, an RNA helicase, and eIF3, a factor binding eIF4G. 
The integrated activity of eIFs recruits the 40S ribosomal subunit on the 5ʹend of the 
mRNA and allows formation of the pre-initiation complex (Dever, 2002). 
Upon overexpression, one of the initiation factors, eIF4E elicits the preferential translation 
of mRNAs with long-structured 5ʹuntranslated regions (UTRs) (D’Ambrogio et al., 2013) 
that usually encode growth factors and proto-oncogenes, like c-myc or cyclin D1 
(Sonenberg, 1993). Knowing that eIF4E initiates the translation of proto-oncogenes 
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(Sonenberg, 1993), its excess is strongly correlated with cancer etiology (Lazaris-Karatzas 
et al., 1992; Ruggero et al., 2004). Proto-oncogenic activity of eIF4E is controlled by 
eIF4E-binding proteins (4EBPs). The 4EBPs impair association of the 40S subunit to the 
cap structure of mRNAs (Teleman et al., 2005) and counteract recruitment of eIF4G 
(Darnell and Richter, 2012). 4EBPs mimic eIF4G, bind the eIF4E, and as a result interrupt 
the eIF4E-eIF4G interaction, which downregulates the translation of many mRNAs 
(Richter and Sonenberg, 2005). Therefore, the key components of the translational 
machinery involved in the initiation step may either promote or suppress cancer formation. 
Translational control is additionally regulated by auxiliary mRNA-binding proteins. One of 
such group of factors is the family of CPEBs (D’Ambrogio et al., 2013).  
 
1.2.2 CPEBs 
Cytoplasmic polyadenylation element binding proteins (CPEBs) are translational factors 
that associate with consensus sequences present in 3’UTRs of mRNAs and regulate their 
translation (Darnell and Richter, 2012; Richter, 2007). The family of CPEBs in vertebrates 
comprises four genes. Each member of the family consists of an N-terminal regulatory 
domain and a C-terminal RNA binding domain (Fig. 1.2.2-1) (Kaczmarczyk et al., 2016; 
Theis et al., 2003). Although all CPEBs have two RNA recognition motifs (RRM), and two 
zinc fingers (ZnF), vertebrate CPEB 2–4 are more closely related to each other, forming a 
subfamily (Huang et al., 2006; Mendez and Richter, 2001), whilst CPEB1, the founding 
member of the family, is evolutionarily most distinct. CPEBs were first discovered in 
Xenopus laevis oocytes, where they control meiosis (Hake and Richter, 1994; Stebbins-
Boaz et al., 1996). CPEB 2-4 display ~98% sequence similarity in RRMs and 
phosphorylation sites (Theis et al., 2003). In addition, these proteins possess common 
splicing patterns (Wang and Cooper, 2010), similar miRNA regulatory motifs (Morgan et 
al., 2010) and overlapping mRNA targets, between themselves and CPEB1 (Fernández-
Miranda and Méndez, 2012; Igea and Méndez, 2010; Novoa et al., 2010; Theis et al., 2003; 
Turimella et al., 2015).  
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Figure 1.2.2-1. Structural relationships between CPEBs. CPEBs consist of an N-terminal regulatory 
domain and a C-terminal RNA binding domain containing two conserved RNA recognition motifs, two zinc-
fingers, and poly Q regions corresponding to polyglutamine stretches. CPEBs with identically marked RRMs 
indicate strong similarity. Figure adapted from Ivshina et al., 2014. 
 
1.2.3 Regulation of polyadenylation-induced translation  
Cytoplasmic polyadenylation begins in the nucleus, where CPEB binds into uracil-rich 
(UUUUUAU, or similar) cytoplasmic polyadenylation elements (CPE) present in the 
3’UTR of pre-mRNAs. Like most of the nuclear pre-mRNAs, the CPEB bound mRNAs 
have ~100 nucleotides long poly(A) tails (Lin et al., 2010). The cleavage and 
polyadenylation specificity factor (CPSF) associates with the AAUAAA sequence of 
mRNA and together with CPEB and Maskin shuttle to the cytoplasm (Lin et al., 2012). 
Following export, CPEBs recruit a number of molecules including symplekin, a scaffold 
protein, Gld2, a germline development 2 non-canonical poly(A) polymerase and PARN, a 
poly(A) ribonuclease to form the ribonucleoprotein (RNP) complex (Fig. 1.2.3-1) (Darnell 
and Richter, 2012; Kim and Richter, 2006).  
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Figure 1.2.3-1. Polyadenylation-induced translation regulated by CPEB1. Cytoplasmic polyadenylation 
begins in the nucleus, where CPEB1 binds to the CPE elements present in 3ʹUTR of pre-mRNA. CPSF 
associates with the AAUAAA nuclear pre-mRNA cleavage and polyadenylation site. CPEB1 recruits RNP 
complex molecules, including symplekin, Gld2 polymerase, PARN ribonuclease and Maskin containing 
4EBP activity. PARN activity shortens the long poly(A) tails added to the mRNA in the nucleus. Whereas 
Maskin binds eIF4E at the eIF4G binding site and thus inhibits translation initiation. Figure from 
D’Ambrogio et al., 2013. 
 
Both of the RNP complex enzymes, PARN deadenylase and Gld2 polymerase are 
catalytically active. When the robust PARN activity exceed the activity of Gld2 
polymerase, it shortens the poly(A) tails on CPE-containing RNAs to 20-40 nucleotides, 
thereby locks mRNAs in a dormant state (Kim and Richter, 2006). Hormonal stimulation 
leads to Aurora kinase A activation and phosphorylation of CPEB1 on serine 174 (Mendez 
et al., 2000a; Sarkissian et al., 2004). These modifications result in expulsion of PARN 
deadenylase from the RNP complex (Kim and Richter, 2006). As a consequence, Gld2 
catalyzes polyadenylation and poly(A)-binding protein (PABP) associates with the newly 
elongated poly(A) tail (Barnard et al., 2004; Kim and Richter, 2006, 2007). The length of 
the poly(A) tail is correlated with the ribosome density and association of PABPs. Changes 
in the RNP complex potentiate the assembly of the initiation complex at the 5’end of the 
mRNA at the expense of the Maskin-eIF4E interaction (Fig. 1.2.3-2) (Cao and Richter, 
2002; Kim and Richter, 2007). Phosphorylation of Maskin allows for its dissociation from 
eIF4E and beginning or resuming translation (Cao et al., 2006). Cytoplasmic 
polyadenylation takes place in sequential waves and is synchronized with the partial 
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destruction of CPEB, the number and location of CPEs within a 3’UTR, and the presence 
of other RNA binding proteins (Ivshina et al., 2014). 
 
 
 
Figure 1.2.3-2. Polyadenylation-induced translation regulated by CPEB1. The RNP complex remains 
dormant until cell stimulation. Stimulation activates Aurora kinase A, which further phosphorylates CPEB1. 
PARN is removed from the complex and that allows Gld2-mediated polyadenylation. PABP and eIF4G attach 
to the newly elongated poly(A) tail. eIF4G replaces Maskin from eIF4E and, through the eIF3 complex, shifts 
the 40S ribosomal subunit to the 5ʹ end of the mRNA. Figure from D’Ambrogio et al., 2013 
 
1.3 Role of CPEBs in germline and somatic cells 
1.3.1 CPEBs in cell cycle progression  
In vertebrates, meiotic cell divisions occur in the absence of transcription, but depend on 
translational control of mRNAs. Many of these mRNAs may undergo regulation by CPEBs 
(Novoa et al., 2010). In Xenopus oocytes, CPEBs mediate both, meiotic progression and 
mitotic divisions. For instance, entry into the M phase is guided by CPEB1 phosphorylation 
by Aurora kinase A, while switch from M to S phase is regulated by CPEB1 
dephosphorylation catalyzed by protein phosphatase 2A (Cao et al., 2006; Groisman et al., 
2002). As oocyte maturation is similar to the somatic cell cycle (Liu and Maller, 2005; 
Peng and Maller, 2010) apart from meiosis, CPEBs were detected in mitosis of mammalian 
cells (Giangarrà et al., 2015; Groisman et al., 2002; Novoa et al., 2010). Based on this 
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finding, cytoplasmic regulation of the poly(A) tails length is not only needed to compensate 
for the lack of transcription in cell divisions but is a general mechanism of controlling cell 
cycle progression (Novoa et al., 2010). In addition to CPEB1, CPEB2 and CPEB4 were 
recently found to be necessary in the phase-specific polyadenylation and translational 
activation in the mitotic cell cycle. Accordingly, CPEB1 is essential for entrance into 
prophase, CPEB2 for metaphase and CPEB4 for cytokinesis (Giangarrà et al., 2015). 
 
1.3.2 CPEBs in metabolism and senescence 
In contrast to normal cells that generate energy required for cellular processes by 
mitochondrial oxidative phosphorylation, cancer cells rely on anaerobic glycolysis (Vander 
Heiden et al., 2009). Human primary fibroblasts with reduced CPEB1 expression 
demonstrated lower mitochondria number, which resulted in decreased respiration rates. 
Interestingly, ATP content remained unchanged. To maintain constant ATP level, cells 
increased glycolysis while reducing oxygen consumption. This process, known as the 
Warburg effect, is characteristic for transformed cancer cells (Burns and Richter, 2008). 
Metabolic balance between mitochondrial respiration and glycolysis is mediated by 
mRNAs containing CPEs, such as p53 and c-myc (Burns and Richter, 2008; Groisman et 
al., 2006). Therefore, knockout of CPEB1 in mouse embryonic fibroblasts (MEF) results in 
reduced polyadenylation and translation of p53 mRNA that subsequently renders cells 
immortal and escaped senescence (Groisman et al., 2006; Ivshina et al., 2014).  
During increased oxidative stress CPEB1 and CPEB2 bind to the hypoxia-inducible factor-
1α (HIF-1α) mRNA and regulate its expression (Hägele et al., 2009). HIF-1α regulates 
homeostatic responses to oxidative stresses, by stimulating transcription of genes involved 
in angiogenesis, metabolism and cell survival. At normal oxygen concentration, HIF-1α is 
continuously synthesized at a reduced level and undergoes proteasome-mediated 
degradation. This type of protein synthesis confirms that HIF-1α mRNA remains ribosome-
associated, thereby promoting quick responses to stress. Under hypoxia or increased 
oxidative stress, the level of HIF-1α is immediately increased (Chen and Huang, 2012; 
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Chen et al., 2015). Thus, by regulating HIF-1α (Chen et al., 2015) or p53 (Burns and 
Richter, 2008) CPEBs mediate important alterations in cellular metabolism.  
 
1.3.3 CPEBs in cancer 
CPEBs mediate control of cellular senescence, proliferation, and migration (Fernández-
Miranda and Méndez, 2012; Jones et al., 2008), thus alterations in their expression are 
crucial for malignant transformation. Recently published meta-analysis shows the extensive 
correlation between the level of CPEB mRNA expression and human cancers (Fig. 1.3.3-1) 
(D’Ambrogio et al., 2013). CPEB expression is downregulated in many tumors, affecting 
the reproductive and digestive system, head and brain, including gliomas. Transcript 
expression level of CPEB1, CPEB2 and CPEB3 appears to be reduced in gliomas and only 
CPEB4 expression is upregulated in oligo-lineage tumors (D’Ambrogio et al., 2013). 
Downregulation of CPEB1 was observed in several types of human tumors, including 
ovarian and gastric, as well as in breast-, myeloma- and colorectal cancer-derived cell lines 
(Caldeira et al., 2012; Hansen et al., 2009; Heller et al., 2008), where it was associated with 
the capacity of malignant cells to promote invasion and angiogenesis (Caldeira et al., 2012). 
Moreover, by mediating apical localization and translation of zona occludens-1 (ZO-1) 
mRNA, CPEB1 participates in maintaining the polarity of mammary epithelial cells. In the 
absence of CPEB1, a randomly distributed ZO-1 mRNA cause the loss of cell polarity 
(Nagaoka et al., 2012) that further leads to an epithelial-to-mesenchymal transition (EMT) 
(Nagaoka et al., 2016). This often results in cell dedifferentiation and metastasis (Tam and 
Weinberg, 2013). Therefore, deprivation of CPEB1 in mammary epithelial cells changes 
the gene expression profile and increases its metastatic potential (Nagaoka et al., 2016). 
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Figure 1.3.2-1. CPEB expression in cancers. Blue color indicates downregulation, while red color indicates 
upregulation of CPEB mRNA levels in cancer after comparison with reference samples. Figure adapted from 
the D’Ambrogio et al., 2013. 
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Thus far, CPEB2 was found to be involved in the progression of breast cancer. One study 
showed that CPEB2 downregulates TWIST1, a transcription factor that supports epithelial 
to mesenchymal transition, during oncogenesis but not in metastatic cells (Nairismägi et al., 
2012). Moreover, CPEB2 regulates metastatic potential of human triple negative breast 
cancer (TNBC) cells (Johnson et al., 2015). The high metastatic potential of TNBC cells is 
especially correlated with increase in expression of CPEB2 isoform lacking the B-region. 
Downregulation of the CPEB2b induces cell death, whereas overexpression of the CPEB2b 
increases metastatic potential of TNBC cells (Johnson et al., 2015). 
Cancer etiology is also mediated by CPEB4. Its expression is increased in GBMs and 
pancreatic ductal carcinomas (PDA). PDA tumors have particularly elevated translation of 
tissue plasminogen activator (tPA) mRNA that is regulated by CPEB4. tPA is absent in 
normal pancreas but overexpressed in most of PDA, where it supports tumor 
vascularization and cells proliferation, migration, and invasion. The expression of CPEB4 
is absent in normal astrocytes, but abundant in high-grade gliomas. CPEB4 mediates tumor 
growth and vascularization in GBMs. Downregulation of CPEB4 levels results in reduction 
of tumor size, cellular proliferation and microvessel density (Ortiz-Zapater et al., 2011; 
Fernández-Mirandaa and Méndez, 2012). Other mRNAs linked to tumorigenesis regulated 
by CPEB4 include Smad3, B-cell lymphoma 2 (Bcl-2), and matrix metallopeptidase 7 
(MMP7) (Ortiz-Zapater et al., 2011). Therefore CPEB4 seems to have a significant role in 
the development of tumors, and might be the element of a more general mechanism of 
carcinogenesis. 
In summary, all CPEBs are involved in growth of cancer, but it is noteworthy that CPEB3 
is not well investigated, yet. Furthermore, although CPEB isoform are structural very 
similar, they are functionally different (Ivshina et al., 2014). 
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1.3.4 CPEBs in the nervous system  
Long-term memory formation takes place in the hippocampus and requires new protein 
synthesis to modulate synaptic plasticity (Kang and Schuman, 1996). Synaptic plasticity is 
the ability of synapses to undergo morphological and biochemical changes in response to 
stimulation (Kandel, 2001; Mayford et al., 2012; Richter and Klann, 2009; Sutton and 
Schuman, 2006). Then the newly synthesized proteins either constitute the synaptic tags or 
influence synaptic activity (Ivshina et al., 2014). 
At the postsynaptic sites of hippocampal neurons reside mRNA molecules. Their 
translation might be initially repressed by CPEB binding, and activated in response to 
synaptic stimulation (Huang et al., 2002; Richter, 2001; Udagawa et al., 2012; Wu et al., 
1998). CPEB1, Gld2, and Neuroguidin comprise a complex that regulates mRNA 
translation at synapses and, thereby, synaptic efficacy. Several important mRNAs undergo 
activity-dependent polyadenylation, including calcium-calmodulin protein kinase II 
(CaMKII), tissue plasminogen activator (tPA) or GluN2A (N-methyl-D-aspartate (NMDA) 
receptor subunit) that is crucial for synaptic plasticity (Du and Richter, 2005; Shin et al., 
2005; Wu et al., 1998).  
CPEB1 represses translation until glutamatergic activation initiates its phosphorylation by 
either Aurora kinase A (Huang et al., 2002; Mendez et al., 2000a) or CaMKII (Fig. 1.3.4-1) 
(Atkins et al., 2004, 2005). Upon stimulation, CPEB1 induces long-term potentiation, 
GluN2A mRNA translation (Udagawa et al., 2012) and the latter is inserted into the 
synaptic membrane as an NMDA receptor subunit (Swanger et al., 2013). The CPEB1 
protein is responsible for dendritic transport of mRNAs. Therefore, CPEB1 associates with 
the motor proteins, kinesin and dynein and transport curtail mRNAs as CaMKII in into 
dendrites (Huang et al., 2003; Ivshina et al., 2014). The contribution of CPEB1 to local 
protein translation is confirmed by its localization in dendrites (Wu et al., 1998) and 
enrichment of phospho-CPEB1 in a fraction of postsynaptic density of neurons (Atkins et 
al., 2004, 2005; Darnell and Richter, 2012). 
Knockout (KO) of CPEB1 activity in mouse models leads to defects in synaptic plasticity, 
learning, and memory (Alarcon et al., 2004; Berger-Sweeney et al., 2006; Darnell and 
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Richter, 2012). However, KO of another CPEB, CPEB3 results in enhancement of 
hippocampus-dependent learning. This process is possibly induced by expression of 
plasticity-regulating molecules, including PSD-95 and the NMDA receptor subunit GluA1, 
previously shown to be regulated by CPEB3 (Huang et al., 2006). KO of CPEB4 has no 
effect on hippocampal plasticity or on learning and memory (Ivshina et al., 2014; Tsai et 
al., 2013).  
 
 
Figure 1.3.4-1. Impact of CPEB1 in neurons. The RNP complex containing CPEB1 is transported in 
dendrites along microtubules by the motor proteins - kinesin and dynein. Synapse stimulation and cytoplasmic 
polyadenylation initiate GluN2A, CaMKII and NDUFV2 activation. GluN2A encodes an NMDA receptor 
subunit, CaMKII, is associated with the postsynaptic density and has kinase activity while NDUFV2 is a part 
of mitochondrial electron transport chain that supplies ATP. Figure from Ivshina et al., 2014. 
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1.4 Alterations regulating expression and activity of CPEBs 
1.4.1 DNA methylation  
Heritable alterations in gene function that occur without modification in the DNA sequence 
are called epigenetic changes. To the major epigenetic mechanisms belong: DNA 
methylation, histone modifications, and RNA-mediated gene silencing (Sharma et al., 
2010). Methylation is the most common covalent modification of DNA in eukaryotes that 
plays an important role in biological processes, including genomic imprinting (Wilkins, 
2005), aging (Jung and Pfeifer, 2015) and cancerogenesis (Chen et al., 2014). DNA 
methylation occurs at cytosine residues, in the cytosine-phosphate-guanine (CpG) 
dinucleotides (Fig.1.4.1-1) (Weber et al., 2007). CpG dinucleotides are concentrated in the 
genome in the CpG-rich DNA fragments called CpG islands, which are clustered around 
gene regulatory regions (Weber et al., 2007; Yamada et al., 2004).  
 
 
Figure 1.4.1-1. Cytosine methylation pathway. Methylation of DNA occurs at cytosine residues, in CpG 
dinucleotides. Upon a reaction catalyzed by the DNA methyltransferases, cytosine is converted to 5-methyl 
cytosine. As a result the methyl group donor, S-adenosylmethionine, is transformed into S-
adenosylhomocytosine. 
 
Methylation is catalyzed by DNA methyltransferases (DNMT), including DNMT1, 
DNMT3A and DNMT3B. DNMT1 is required to maintain the methylation status, while 
DNMT3A and DNMT3B are needed for de novo DNA methylation during the embryo 
formation process (Bernstein et al., 2007; Chen et al., 2014). Generally, methylation takes 
place during DNA replication. Following replication, DNMT1 (Goll and Bestor, 2005) 
complements the missing methylation on the newly synthesized strand. It allows 
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maintenance of DNA methylation patterns through many rounds of cell division (Zilberman 
and Henikoff, 2007). Methylation does not alter nucleotide sequences and does not affect 
the specificity of DNA base pairing (Chen et al., 2014). 
In normal cells, regions of the gene promoter containing CpG islands are commonly not 
methylated, while coding regions are often methylated. This is to sustain the 
transcriptionally active euchromatin structure (Fig. 1.4.1-2). A reverse methylation pattern 
is observed in cancer. Cancerous cells undergo alterations in promoter methylation that 
result in abnormal gene expression and a malignant phenotype. Genomic hypomethylation 
of proto-oncogenes usually results in genome instability and their enhanced expression 
(Ehrlich, 2002). In contrast, local promoter hypermethylation results in functional silencing 
of tumor-associated genes. Enhanced methylation at the promoter region results in their 
inactivation by change in the open euchromatin conformation to a compact heterochromatin 
structure (Fig. 1.4.1-2) (Chen et al., 2014). Therefore, DNA hypermethylation suppresses 
the activity of genes transcription though blocking the binding of a transcription factor 
(Herman and Baylin, 2003; Watt and Molloy, 1988), or by recruiting methylation binding 
proteins that support inhibition of gene expression (Nan et al., 1998). 
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Figure 1.4.1-2. DNA methylation in normal and cancer cells. In normal cells, regions of the gene 
promoters containing CpG islands are commonly not methylated. This is to sustain the transcriptionally active 
euchromatin structure. Cancer development drives hypermethylation of many genes. Increased methylation at 
the promoters regions containing CpG islands results in their inactivation. Through changing of the open 
euchromatin conformation to a compact heterochromatin structure expression of these genes is silenced. On 
the illustration above, cytosine residues are marked with C, while 5-methyl cytosine residues are marked with 
M. Figure from Chen et al., 2014.  
 
1.4.2 Alternative splicing  
The process of removing introns and joining exons in pre-mRNA complexes is known as 
splicing. RNA splicing is controlled by splice sites, the specific sequences present at the 
intron-exon borders, and carried out by spliceosomes, the complexes that assemble around 
splice sites at introns and catalysis the splicing reaction (Wessagowit et al., 2005). 
Depending on the similarity to the canonical splicing consensus sequences, splice sites are 
considered to be strong or weak (Kornblihtt et al., 2013). The strong splice sites allow 
identification of consensus sequences that leads to the constitutive splicing, while the weak 
splice sites are suboptimal for consensus sequences and their use depends on the cellular 
context (Wessagowit et al., 2005). The proximity of competing weak and strong sites along 
the pre-mRNA allows the synthesis of numerous gene transcripts with different properties 
(Kornblihtt et al., 2013). Therefore, alternative splicing of pre-mRNA molecules forms an 
additional level of regulation that occurs between transcription and translation (Berget et 
al., 1977; Chow et al., 1977). This process tightly controls expression of multiple mRNA 
variants from a single gene and determines signal transduction and chromatin modification 
(Kornblihtt et al., 2013). However, in the cell itself this is not clearly separated because 
splicing and alternative splicing are combined with transcription, thus factors that regulate 
transcription also affect alternative splicing (Kornblihtt et al., 2013). 
All four CPEB genes are subject to alternative splicing (Theis et al., 2003; Turimella et al., 
2015; Wang and Cooper, 2009, 2010), however the biological importance of this 
phenomenon is not fully known. Alternative splicing leads to differences in the protein 
sequence, affecting further their function and altering where, and how CPEBs bind with 
their target mRNAs (Wang and Cooper, 2010). Alternative splicing of CPEBs is 
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particularly relevant in the context of cytoplasmic polyadenylation. This is because the 
alternatively spliced regions contain regulatory phosphorylation sites (Kaczmarczyk et al., 
2016; Skubal et al., 2016; Theis et al., 2003; Turimella et al., 2015).  
Regions of high similarity between CPEB 2-4 are found in the 8-aa B-region. Less 
similarity is observed in the 17-30-aa C-region. The hexamer and octamer sequences 
present in the RRMs, as well as the linkers between RRMs are similar, thus it is possible 
that CPEB 2-4 share the same regulatory mechanisms and target similar populations of 
RNAs (Fig. 1.4.2-1). Compared to CPEB 2-4, CPEB1 demonstrates significant differences 
within the described domains. This implies that CPEB1 may not only be involved in 
different mechanisms for RNA interaction, but also recognizes different targets (Wang and 
Cooper, 2010). CPEB1 harbors a site for alternative splicing in the RRM. For CPEB1, the 
full-length isoform (Gebauer and Richter, 1996) and the isoform with 5-aa deletion in 
RRM1 (Δ5) (Wilczynska et al., 2005) have been described. The N-terminal regulatory 
domain of CPEB 2-4 harbor regions of alternative splicing and give rise to multiple splice 
isoforms. Alternative splicing of CPEB 2-4 results in either inclusion or removal of the C- 
and B-region and gives rise to four splice variants including a (full length), b (lacking the 
B-region), c (lacking the C-region), and d (lacking both regions) (Theis et al., 2003; Wang 
and Cooper, 2010). Recent studies report that CPEB2 contains and additional 3-aa long 
region that undergoes alternative splicing, however its function is unknown (Turimella et 
al., 2015).  
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Figure 1.4.2-1. Comparison of mouse CPEB 1-4 containing regions undergoing alternative splicing. The 
alternatively spliced 17-30-aa long regions are marked in blue, 8-aa in red, 9-aa in orange. The underlined 
sequences refer to RRMs. The RRMs regions labeled in grey are consensus hexamer and octamer sequences. 
Asterisks mark perfect matches, colons indicate substitutions with similar amino acids, and gaps represent 
substitutions with distinct amino acids. Figure from Wang and Cooper, 2010. 
1.4.3 Phosphorylation 
Phosphorylation has been previously shown to regulate the activity of CPEBs (Theis et al., 
2003). In Xenopus oocytes, CPEBs undergo phosphorylation by Aurora kinase A on serine 
174, which subsequently triggers cytoplasmic polyadenylation and translation (Kim and 
Richter, 2006; Mendez et al., 2000b). In mouse brain, upon NMDA receptor activation, 
CPEB1 is phosphorylated and activated by Aurora A or CaMKII kinase (Tay and Richter, 
2001; Tay et al., 2003; Hodgmanet al., 2001; Kaczmarczyk et al, 2016). The structural and 
functional differences that influence CPEB phosphorylation are generated during 
alternative splicing (Wang and Cooper, 2010). The splice variants of CPEB 2-4 differ 
Introduction 
 
 
36 
 
between each other by the presence or absence of B- and C-regions (Fig. 1.4.3-1). 
Especially important is the B-region located upstream of the two serine residues, that 
harbors the kinase recognition sites for cyclic AMP-dependent protein kinase A (PKA), 
protein kinase B (PI3K/Akt), ribosomal S6 kinase (RPS6K) and CaMKII (Kaczmarczyk et 
al., 2016; Theis et al., 2003; Wang and Cooper, 2010).  
 
 
 
Figure 1.4.3-1. Comparison of CPEB3 isoforms in mouse brain. The CPEB3 isoform differs by the 
presence or absence of the alternatively spliced B- and C-regions. Splicing results in expression of four 
isoforms, including CPEB3a (containing both regions), CPEB3b (lacking the B-region), CPEB3c (lacking the 
C-region), and CPEB3d (lacking both regions). Phosphorylated residues S419 and S420 are marked by an 
asterisk, the consensus phosphorylation sites for PKA and CaMKII kinase are labeled above the alignment. 
Figure from Kaczmarczyk et al., 2016. 
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2 AIM OF THE STUDY 
 
The present study aimed at elucidating principles of translational regulation by CPEBs and 
their function in the healthy brain and in tumor tissue. Three main aspects were investigated 
in detail. 
Expression of CPEBs in the context of human glioma pathogenesis recently became an 
object of intensive investigation, and first reports already pre-described CPEB expression 
patterns (Galardi et al., 2016; Hu et al., 2015). However, the question how CPEB 
expression is regulated in gliomas remains largely unanswered. Therefore, the first part of 
the present work aimed at determining CPEB expression patterns in high- and low-grade 
human gliomas and assessing a potential contribution of CPEBs to the survival of glioma 
patients. Selected mechanisms involved in the regulation of CPEBs, such as methylation, 
alternative splicing and phosphorylation were subjected to further analysis. DNA 
methylation was considered due to its role in transcriptional silencing of tumor suppressor 
genes (Baylin, 2005), while analysis of phosphorylation and alternative splicing were 
relevant in the context of cytoplasmic polyadenylation (Kaczmarczyk et al., 2016). 
Although altered expression of CPEBs in gliomas unequivocally indicates the importance 
of translational regulation in the brain tumors, the exact impact of CPEB dysregulation on 
GBM cells is unclear. Therefore the second part of the present study aimed at investigating 
the relationship between CPEB activity, growth properties and cancer-relevant parameters 
in a simplified cell culture model. The answer to the question whether overexpression of 
CPEB1 and CPEB2 in cultured GBM cells is associated with the change of cancer-related 
signaling pathways may help identifying new putative CPEB targets. Likewise, inquiring 
the effect of potential CPEB1 and CPEB2 overexpression on migration, apoptosis and 
proliferation may provide important information about the characteristics of altered CPEB 
expression in GMB cells. 
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All members of CPEB family are expressed in the mouse hippocampus, a region crucial for 
memory formation (Theis et al., 2003). In this context, CPEB1 was implicated in regulation 
of the local protein synthesis (Theis et al., 2003; Udagawa et al., 2012). However, beyond a 
general description, not much is known about the function of other family members. The 
main objective of the final part of the study was to determine the CPEB2 expression profile 
in mouse brain. Additionally, the study intended to validate whether CPEB2 subcellular 
localization resembles CPEB1 expression in primary hippocampal cultures and whether 
CPEB2 expression varies between different cellular populations, brain regions, and stages 
of development. 
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3 MATERIALS 
 
3.1 Antibodies 
 
Table 3.1-1. Primary antibodies 
 
antigen host type concentration application company catalogue no. 
       
CPEB1 Rb P 1:100 ICC, IHC, 
WB 
Eurogentec, 
Cologne 
custom-made 
CPEB2 Rb P 1:250 (ICC),  
1:50 (IHC, WB) 
ICC,  
IHC, WB 
Eurogentec, 
Cologne 
custom-made 
CPEB3 Rb P 1:100 ICC, IHC, 
WB 
Abcam, 
Cambridge 
ab10833 
CPEB4 Rb P 1:250 ICC, IHC Eurogentec, 
Cologne 
custom-made 
GFP Ch P 1:500 IHC Abcam, 
Cambridge 
ab13970 
MAP2 Ms M 1:100 IHC Sigma,  
Saint Louis 
M4403 
PARP Ms M 1:5 FACS BD Biosciences, 
San Jose 
552933 
PARV Ms M 1:250 IHC Millipore, 
Temecula 
MAB1572 
PKA Rb P 1:500 IHC Abcam, 
Cambridge 
ab59218 
pHH3 Rb P 1:20 FACS Cell Signaling, 
Danvers 
9716 
antigen host type concentration application company catalogue no. 
       
phospho- Rb M 1:1000 IHC Cell Signaling, 3361 
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CaMKII Danvers 
phospho-
CPEB3 
Rb P 1:50 ICC, IHC, 
WB 
Eurogentec, 
Cologne 
custom-made 
TYH Ms M 1:500 IHC Millipore, 
Temecula 
MAB318 
 
Ch: chicken; M: monoclonal antibody; Ms: mouse: P: polyclonal antibody; PARP: anti-cleaved 
poly(ADP-ribose) polymerase (Asp214); PARV: anti-parvalbumin; pHH3: phospho-histone H3 
(Ser10); Rb: rabbit; TYH: anti-tyrosine hydroxylase 
 
Table 3.1-2. Custom primary antibodies 
 
antigen peptide sequence 
  
CPEB1 RGIHDQLPDFQDSEETVT 
CPEB2 LQLPAWGSDSLQDSWC 
CPEB4 KPPSPWSSYQSPSPTP 
phospho-CPEB3 RRGRSSLFPFED 
 
Table 3.1-3. Secondary antibodies 
 
antigen host concentration application company catalogue no. 
      
Alexa 488 goat anti-
mouse 
1:500 ICC Invitrogen, 
Rockford 
A11006 
Alexa 488 goat anti-
rabbit 
1:500 ICC Invitrogen, 
Rockford 
A11034 
      
antigen host concentration application company catalogue no. 
      
Alexa 568 goat anti-
mouse 
1:500 ICC Invitrogen, 
Rockford 
A11031 
Alexa 568 goat anti-
rabbit 
1:500 ICC Invitrogen, 
Rockford 
A11011 
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Alexa 594 goat anti-
mouse 
1:500 ICC Invitrogen, 
Rockford 
A11032 
Alexa 594 goat anti-
rabbit 
1:500 ICC Invitrogen, 
Rockford 
A11037 
IgG HRP goat anti-
mouse 
1:10 000 WB GE Healthcare, 
Amersham 
31430 
IgG HRP goat anti-
rabbit 
1:10 000 WB GE Healthcare, 
Amersham 
31460 
 
3.2 Cell cultures  
3.2.1 Reagents 
 
Dulbecco’s Modified Eagle Medium with 25 mM glucose (DMEM) Gibco, Darmstadt 
Dulbecco’s Phosphate Buffered Saline (DPBS) Gibco, Darmstadt 
Fetal Calf Serum heat-inactivated (FCS) Gibco, Darmstadt 
L-Glutamine Gibco, Darmstadt 
MEM Non-Essential Amino Acids (NEAA) Gibco, Darmstadt 
MEM Sodium Pyruvate Gibco, Darmstadt 
Opti-MEM (Reduced Serum Medium) Gibco, Darmstadt 
Penicillin/Streptomycin Gibco, Darmstadt 
Trypsin-EDTA 0,05% Gibco, Darmstadt 
 
3.2.2 Media composition 
 
MEF cell culture medium: 
 DMEM with 25 mM glucose 500 ml 
 FCS (heat-inactivated) 10% 
 L-Glutamine 6 mM 
 MEM Non-Essential Amino Acids 0.1 mM 
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 MEM Sodium Pyruvate 1 mM 
 Penicillin/Streptomycin 1% 
 
Trans-MEF cell culture medium: 
 DMEM with 25 mM glucose 500 ml 
 FCS (heat-inactivated) 2% 
 L-Glutamine 6 mM 
 MEM Non-Essential Amino Acids 0.1 mM 
 MEM Sodium Pyruvate 1 mM 
 Penicillin/Streptomycin 1% 
 
Serum-starved MEF cell culture medium: 
 DMEM with 25 mM glucose 500 ml 
 FCS (heat-inactivated) 1% 
 L-Glutamine 6 mM 
 MEM Non-Essential Amino Acids 0.1 mM 
 MEM Sodium Pyruvate 1 mM 
 Penicillin/Streptomycin 1% 
 
Opti-MEM with 5% FBS:  
 Opti-MEM  500 ml 
 FCS (heat-inactivated) 5% 
Opti-MEM with 10% FBS and 1%NEAA:  
 Opti-MEM 500 ml 
 FCS (heat-inactivated) 10% 
 MEM Non-Essential Amino Acids 0.1 mM 
 
3.2.3 Cell culture consumables 
 
6-well plate Thermo Fisher Scientific, Roskilde 
24-well plate Thermo Fisher Scientific, Roskilde 
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96-well plate Thermo Fisher Scientific, Roskilde 
50 ml, 25 cm3 flask Greiner Bio-One, Frickenhausen 
2 ml serological pipette Greiner Bio-One, Frickenhausen 
5 ml serological pipette Costar Stripette, Corning 
10 ml serological pipette Greiner Bio-One, Frickenhausen 
25 ml serological pipette Costar Stripette, Corning 
1 ml syringe BD Plastipak, Madrid 
25 ml tube Greiner Bio-One, Frickenhausen 
50 ml tube Greiner Bio-One, Frickenhausen 
cell scraper Sarstedt, Newton 
glass pipettes Carl Roth, Karlsruhe 
hypodermic needle,  27G Braun, Melsungen 
microscopic slides  Thermo Fisher Scientific 
pipettes BRAND, Wertheim 
pipette tips  Greiner Bio-One, Frickenhausen 
 
 
 
 
3.3 Chemicals 
 
Chemicals were purchased from AppliChem (Darmstadt), Carl Roth (Karlsruhe) and 
Sigma-Aldrich (Saint Louis). Cell culture media, antibiotics and serum were purchased 
from Gibco (Darmstadt). Primers were purchased from Biolegio (Nijmegen) and 
Eurogentec (Cologne). 
 
3.4 Extraction of nucleic acids  
 
RNeasy Mini Kit Qiagen, Hilden 
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content:  
 Buffer RLT 
 Buffer RW1 
 Buffer RPE 
 RNase-Free Water 
 
3.5 Fragment analysis 
3.5.1 Reagents 
 
ddH2O Fresenius Kabi, Bad Homburg 
50 mM MgCl2 Invitrogen, Carlsbad 
10 mM dNTP Invitrogen, Carlsbad 
5x First-Strand Buffer  Invitrogen, Carlsbad 
PlatinumTaq DNA Polymerase Invitrogen, Carlsbad 
 
 
 
3.5.2 Primers 
 
Table 3.5.2-1. Primers for CPEB1-4 alternative isoforms identification  
 
primer sequence binding 
position 
predicted 
length 
genebank 
association no. 
detected 
length 
isoform 
      
CPEB1      
fw 5’ GGATTGGTTAACACCTTCCGTGTTTTTGGC 3’ 
 967 (v1)     
 751 (v2)     
rev 5’ AGGCCATCTGGGCTCAGCGGG 3’ 
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 1131 (v1) 176 bp (v1) NM_030594 169 bp Δ5 
 921 (v2) 191 bp (v2) NM_001079533 182 bp full-length 
      
CPEB2      
fw 5’ AACTCCATCACTGACTCCAAAATCT 3’ 
 1860     
rev 5’ CAAGCCATCATCTATTGGAAAGAGGGAAGA 3’ 
 2206 375 bp (v4) NM_001177382 375 bp 2a 
 2182 352 bp (v2) NM_182485 351 bp 2b 
 2125 295 bp (v3) NM_001177381 294 bp 2 c* 
 2116 286 bp (v5) NM_001177383 286 bp 2c 
 2101 271 bp (v6) NM_001177384 271 bp 2d* 
 2092 262 bp (v1) NM_182646 262 bp 2d 
 
 
 
 
  
 
 
  
      
primer sequence binding 
position 
predicted 
length 
genebank 
association no. 
detected 
length 
isoform 
      
CPEB3      
fw 5’ CAAAAAGCCCTTCTCCAGCAAC 3’ 
 876     
rev 5’ TTCAGCTTTGTGAGGCCAGTCTA 3’ 
 1478 604 bp (v1) XM_006717715 600 bp 3a 
 1433 580 bp (v3) XM_011539514 576 bp 3b 
 1388 535 bp * 531 bp 3c 
 1364 511 bp * 507 bp 3d 
      
CPEB4      
fw  5’ CAGCTCTGCCTTTGCACCTAAAT 3’ 
 1053     
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rev  5’ GGCCATCATCCAAGAATCCATC 3’ 
 1309 278 bp (v1) NM_30627 277bp 4a 
 1286 255 bp * 254bp 4b 
 1258 227 bp (v2) NM_001308189 226bp 4c 
 1234 203 bp (v3) NM_001308191 203bp 4d 
 
"fw" and "rev" mark forward and reverse primers, * marks constructs based on a transcript variant 
alignment 
 
 
 
3.6 Immunocytochemistry  
3.6.1 Reagents 
 
DAPI Sigma, Saint Louis 
Hoechst  Life Technologies, Carlsbad 
Mounting Medium, PermaFluor  Thermo Scientific, Fremont 
Normal Goat Serum  Abcam, Cambridge 
Triton X-100  Carl Roth, Karlsruhe 
  
3.6.2 Buffers and solutions 
 
10xPBS (pH 7.4): 
 NaCl 80 g  
 KCl 2 g  
 Na2HPO4 14.4 g 
 KH2PO4 2.4 g  
 dH2O 1l 
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0.01% NaN3 in 1xPBS (pH 7.4): 
 NaN3 0,1 g 
 1xPBS (pH 7.4) 1l 
 
30% sucrose in 1xPBS (pH 7.4):  
 sucrose 30 g 
 1xPBS (pH 7.4) 1l 
 
 
 
4% PFA: 
 PFA 4 g  
 dH2O 90 ml 
 NaOH 1M 
 10xPBS (pH 7.4) 10 ml 
 
poly-L-lysine: 
 poly-L-lysine 500 μl of 2 mg/ml 
 dH2O 50 ml 
 
3.7 Immunohistochemistry  
3.7.1 Reagents 
 
Cytoseal XYL medium Thermo Scientific, Runcorn 
Hematoxylin Merck, Darmstadt 
Permafluor Thermo Scientific, Runcorn 
PT Modul Buffer Medac, Hamburg 
Xylene Merck, Darmstadt 
100% ethanol  AppliChem, Darmstadt 
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90% ethanol  AppliChem, Darmstadt 
70% ethanol AppliChem, Darmstadt 
 
3.7.2 CSA II staining system for immunohistochemistry 
 
CSA II Biotin-free Tyramide Signal Amplification System Dako, Carpinteria 
content:  
 TBS-T (Tris Buffered Saline- Tween) 
 Peroxidase Block 
 Protein Block 
 Anti-Rabbit Immunoglobulins-HRP 
 Amplification Reagent 
 Anti-Fluorescein-HRP 
 DAB Substrate Buffer 
 Liquid DAB Chromogen 
 
3.8 Laboratory equipment 
 
3130 Genetic Analyzer Applied Biosystems, Foster City 
ABI 7900HT fast real time PCR system  Applied Biosystems, Darmstadt 
Advanced Tissue Arrayer  Chemicon, Rolling Meadows 
Axiophot  Carl Zeiss Microimaging GmbH, Göttingen 
Axio Imager Z1 fluorescence microscope  Carl Zeiss Microimaging GmbH, Jena 
BD FACS Canto II digital benchtop analyzer  BD Biosciences, Heidelberg 
Centrifuge HERAEUS  Thermo Fisher Scientific, Schwerte 
Centrifuges  Eppendorf GmbH, Wesseling 
Fast Real-Time PCR System 7900HT  Applied Biosystems, Darmstadt 
Gel electrophoresis chamber  Biorad, Munich 
GeneGenome Syngene Bioimaging  Synaptics ltd. Cambridge 
GeneTools System Synaptics ltd. Cambridge 
GloMax 96 Microplate Luminometer  Promega, Madison 
Heat block  VWR International, Darmstadt 
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Lab Vision PT Modul Thermo Scientific, Fremont 
Leica TCS confocal  Leica Microsystems, Wetzlar 
Mirax Slide Scanner  Carl Zeiss Microimaging GmbH, Jena 
Nanophotometer Pearl  Implen GmbH, München 
Novex Minicell WB module  Invitrogen, Darmstadt 
Olympus BX53 research microscope  Olympus, Tokyo 
PCR machines (MyCycler thermal cycler)  Biorad, München 
pH meter  Mettler Toledo, Giessen 
Pyromark Q24 instrument, Biotage Qiagen, Hilden 
Refrigerators (-80°C)  Thermo Fisher Scientific, Schwerte 
Semi-automated IHC Stainer  Tecan, Crailsheim,  
Shaker  Heidolph Rotomax120, Schwabach 
Shaking incubator (GFL)  Progen Scientific, London 
Shaking water bath Memmert GmbH, Schwabach 
Surgery equipment Fine Science Tools (F.S.T), Heidelberg 
VWR benchtop centrifuge VWR International, Darmstadt  
Thermoblock Biometra, Goettingen 
Vibratome, VT1000S  Leica, Nussloch 
Vortexer  VWR International, Darmstadt 
Mini-Protean 3 cell  Biorad, Munich 
WB power supply  Biorad, Munich 
Weigh balance  Sartorius group, Güottingen 
 
3.9 Methylation  
3.9.1 Bisulfite conversion reagents 
 
EpiTect Fast DNA Bisulfite Kit  Qiagen, Hilden 
content:  
 Bisulfite Solution 
 DNA Protect Buffer 
 Buffer BL 
 Buffer BW  
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 Buffer BD  
 Buffer EB 
 Carrier RNA 
3.9.2 Bisulfite-DNA amplification reagents  
 
ddH2O Fresenius Kabi, Bad Homburg 
PyroMark PCR Kit Qiagen, Hilden 
content:  
 Master Mix 2x 
 CoralLoad Concentrate 10x 
 
3.9.3 Pyrosequencing reagents 
 
Streptavidin-Sepharose High Performance Beads  GE-Healthcare, Solingen 
PyroMark PCR Kit  Qiagen, Hilden 
content:  
 PyroMark Annealing Buffer 
 PyroMark Binding Buffer, pH 7.6  
 PyroMark Denaturation Solution 
 PyroMark Enzyme Mixture  
 PyroMark Nucleotides (dATP, dCTP, dGTP, dTTP) 
 PyroMark Substrate Mixture 
 PyroMark Wash Buffer, pH 7.6 
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3.9.4 Primers 
 
Table 3.9.4-1. Primers for amplification of bisulfite treated DNA 
 
gene primer sequence 
  
CPEB1 fw 5’ GGGGGTTAGAGATTTAAGTTTGAG 3’ 
 rev 5’ ACTCCCATCCAAAAAAAACCAATAATATCT 3’ 
  
CPEB2 fw 5’ GGGGGTTATTAGTTTAAGTGAGAGTG 3’ 
 rev 5’ TCCCCTACCCAAATTCACT 3’ 
  
CPEB3 fw 5’ GGGGGTTATTAGTTTAAGTGAGAGTG 3’ 
 rev 5’ ACCACCAACCCATCATAAC 3’   
  
CPEB4 fw 5’ GGGGAAAAGAGAGAGAAAGT 3’ 
 rev 5’ ACTTCCTCTCCCCCATAA 3’ 
 
"fw" and "rev" mark forward and reverse primers 
 
Table 3.9.4-2. Primers for pyrosequencing 
 
gene primer sequence 
  
CPEB1 ps  5’ AAGAGGGTAAGATTTATAAG 3’ 
CPEB2 ps  5’ TGGGGGAGTGGGAGA 3’ 
CPEB3 ps  5’ CCAACCCATCATAACC 3’ 
CPEB4 ps  5’ GGTTTTAGTATTTTTAG 3’ 
 
"ps" mark pyrosequencing primers 
 
3.10 Pathways activity assay 
 
Cignal 45-Pathway Reporter Array SABioscience, Frederick 
Materils 
 
52 
 
Dual-Luciferase Reporter Assay Promega, Madison 
content:  
PLB 5x Passive Lysis Buffer (PLB) dissolved in 4 volumes of dH2O 
LAR II Luciferase Assay Substrate suspended in Luciferase Assay Buffer II 
Stop & Glo Reagent 200 μl of 50x Stop& Glo Substrate dissolved in10 mL of Stop& Glo 
Buffer 
 
3.11 Semi-quantitative real time PCR 
3.11.1 Reverse transcription reagents 
 
5x First-Strand Buffer Invitrogen, Carlsbad 
0.1 M DTT Invitrogen, Carlsbad 
50 mM MgCl2 Invitrogen, Carlsbad 
10 mM dNTP Invitrogen, Carlsbad 
250 ng Random Hexamer Primer  Invitrogen, Carlsbad 
SuperScript III Reverse Transcriptase Invitrogen, Carlsbad 
ddH2O Fresenius Kabi, Bad Homburg 
 
3.11.2 TaqMan semi-quantitative real time PCR reagents 
 
TaqMan Universal PCR Master Mix Applied Biosystems, Warrington 
900 nM forward primer Eurogentec, Cologne 
900 nM reverse primer Eurogentec, Cologne 
100 nM probe Eurogentec, Cologne 
ddH2O Fresenius Kabi, Bad Homburg 
3.11.3 Primers and probes 
 
Table 3.11.3-1. Primers and probes for semi-quantitative real time PCR 
 
primers and probes sequences binding position length 
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CPEB1; genebank association no: NM_030594 
fw 5’ GCACCCAGGACTCAGATTCC 3’ 335 (v1),  
110 (v2) 
73 bp (v1), 
rev 5’ CCCAGTGGGTTATGGAGCAT 3’ 358 (v1),  
134 (v2) 
73 bp (v2) 
p 5’ CCCAGAGCAGCACACACTCGGTACTG 3’ 358 (v1),  
134 (v2) 
 
   
CPEB2; genebank association no: NM_001177382 
fw 5’ TGCAGCAGAGGAACTCCTATAACC 3’ 1631 (v1-v6) 81 bp (v1-v6) 
rev 5’ CCCAGCCACTGCTCTGATG 3’ 1693 (v1-v6)  
p 5’ CCAGCCTCTTCTGAAACAGTCTCCCTGG 3’ 1659 (v1-v6)  
   
PBGD; genebank association no: NM_000190 
fw 5’ GCTATGAAGGATGGGCAACT 3’ 808 (v1), 
756 (v2), 
688 (v3), 
637 (v4) 
149 bp  
(v1-v4) 
rev 5’ GTGATGCCTACCAACTGTGG 3’ 936 (v1), 
886 (v2), 
817 (v3), 
766 (v4) 
 
p 5’ TGCCCAGCATGAAGATGGCC 3’ 906 (v1), 
855 (v2), 
786 (v3), 
735 (v4) 
 
 
"fw"and "rev" mark forward and reverse primers, "p" probe and "v" transcript variant 
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3.12 Transfection 
3.12.1 Reagents 
 
Forskolin Cell Signaling, Danvers 
Lipofectamine 3000 Transfection Kit Invitrogen, Carlsbad 
Staurosporine S4400 Sigma, Saint Louis 
 
3.12.2 Expression vectors 
 
Table 3.12.2-1. Expression vectors 
 
host insert vector company 
    
human CPEB1 pCMV6Neo OriGene, Rockville 
human CPEB2 pCMV6Neo OriGene, Rockville 
human - pCMV6Neo OriGene, Rockville 
human - pmaxGFP Lonza, Cologne 
mouse CPEB3a pEGFP-N1 Clontech Laboratories, Heidelberg 
mouse CPEB3aKD pEGFP-N1 Clontech Laboratories, Heidelberg 
mouse CPEB3b pEGFP-N1 Clontech Laboratories, Heidelberg 
 
CPEB3a-EGFP, CPEB3aKD-EGFP and CPEB3b-EGFP vectors were generated 
by Dr. Vamshidhar Vangoor (Institute of Cellular Neurosciences, University of 
Bonn), vector maps are provided in appendix I 
 
3.13 Western blotting 
3.13.1 Protein lysis buffer 
 
Protein lysis buffer: 
modified RIPA buffer  
pH 7.5, stored at -20°C  
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 Tris 6.05 g 50 mM 
 NaCl 8.76 g 150 mM 
 NP40  5 ml 0.5% 
 Sodium deoxycholate 5 g 0.5% 
 Triton X-100 10 ml 1% 
 
Halt Protease Phosphatase Single Use Inhibitor Cocktail (Thermo Scientific, Rockford) 
Contents (except NP40 and triton) were dissolved in 800 ml ddH2O; pH was adjusted to 7.5; 
NP40 and Triton X-100 were added; volume was adjusted to 1l; buffer was aliquoted 10 ml 
each and stored at -20
o
C. Modified RIPA lysis buffer was supplemented with Inhibitor 
Cocktail directly before use. 
 
3.13.2 BCA Protein Assay 
 
BCA Protein Assay Kit Thermo Scientific, Rockford 
 
content: 
Albumin Standard 2mg/mL 
BCA Reagent A 
BCA Reagent B 
 
3.13.3 SDS-PAGE and protein transfer 
 
Consumables: 
Methanol  AppliChem, Darmstadt 
PVDF membrane  GE Healthcare Life Sciences, Buckinghamshire 
Roti Load 1 4x Sample buffer  Carl Roth GmbH, Karlsruhe 
Whatman paper  Whatman International, Maidstone 
 
Buffers and solutions: 
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Tris, 1.5 M, pH 8.8: 
 Tris 18.16 g/100 ml dH2O 
 
 
Tris, 0.5 M, pH 6.8: 
 Tris 6.05 g/100 ml dH2O 
 
10% APS: 
 APS 0.1 g/1 ml dH2O 
 
10% SDS: 
 SDS 10 g/100 ml dH2O 
 
Resolving gel (10%): 
 dH2O 7.94 ml 
 1.5 M Tris (pH 8.8) 5 ml 
 10% SDS 0.2 ml 
 Acrylamide 6.66 ml 
 10% APS 0.2 ml 
 TEMED 0.02 ml 
Stacking gel (4%): 
 dH2O 2.81 ml 
 0.5 M Tris (pH6.8) 1.25 ml 
 10% SDS 0.05 ml 
 Acrylamide 0.83 ml 
 10% APS 0.05 ml 
 TEMED 0.005 ml 
 
10x TBS-T, pH 7.4: 
 25 mM Tris 30.3 g 
 150 mM NaCl 87.7 g 
 0.05% Tween-20 10 g 
 dH2O 1l 
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Running buffer: 
10x Tris-Glycine-SDS buffer, pH 8.3: 
 25 mM Tris 30.3 g 
 192 mM Glycine 144 g 
 0.1% SDS 10 g 
 dH2O 1l 
 
Blotting buffer: 
10x Tris-Glycine buffer, pH 8.3: 
 25 mM Tris 30.3 g 
 192 mM Glycine 144 g 
 dH2O 1l 
 
 
 
3.13.4 Blocking and antibody solutions 
 
General blocking solution: 
 5% milk powder 0.5 g 
 1x TBS-T (pH 7.4) 10 ml 
 0.05% Tween-20 0.5 ml 
 
Blocking solution for phospho-specific antibody: 
 3% BSA 0.3 g 
 1x TBS-T (pH 7.4) 10 ml 
 
 
Solution for incubation with primary and secondary antibody: 
 2,5% milk powder 0.25 g 
 1x TBS-T (pH 7.4) 10 ml 
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Solution for incubation with phospho-specific primary antibody: 
 2% BSA 0.2 g 
 1x TBS-T (pH 7.4) 10 ml 
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4 METHODS 
 
4.1 Animals 
Maintenance and handling of animals was according to the local government regulations. 
Animals were housed in a 12 h/12 h dark-light cycle, food and water ad libitum. C57Bl6J 
wild-type mice were purchased from Charler River Laboratories (Sulzfeld). Thy1-GFP 
mice were provided by Prof. Valentin Stein (Institute of Physiology, University of Bonn).  
 
4.2 Cell cultures  
4.2.1 Glioblastoma cell cultures  
Human glioblastoma cell lines A172, A178, LN229, U373MG, U87MG and T98G were 
obtained from the Ludwig Institute for Cancer Research (San Diego). Individual cell lines 
identity was confirmed by STR DNA profiling of 15 loci and sex-determining marker 
amelogenin (Genetica DNA Laboratories, Cincinnati). Cells were grown in DMEM with 25 
mM glucose (Gibco, Darmstadt) supplemented with 10% FCS (Gibco, Darmstadt), 1% 
penicillin/streptomycin (Gibco, Darmstadt), 200 mM L-glutamine (Gibco, Darmstadt) and 
100 mM sodium pyruvate (Gibco, Darmstadt) at 37°C, 5% CO2.  
 
4.2.2 HEK-293FT cell cultures 
Cultured HEK-293FT cells were grown in DMEM with 25 mM glucose supplemented with 
10% FCS, 1% penicillin/streptomycin, 200 mM L-glutamine and 100 mM sodium pyruvate 
at 37°C, 5% CO2. 
 
Methods 
 
60 
 
4.2.3 Primary hippocampal cultures 
Primary hippocampal cultures were provided by Prof. Susanne Schoch (Institute of 
Neuropathology, University of Bonn). 
 
4.3 Human specimens  
Human glioma specimens were received from 69 patients (26 females, 43 males) admitted 
to the University Hospital of Bonn (ethics volume no. FKZ. 01GS08187). Histological 
characterization performed by neuropathologists of the German Brain Tumor Reference 
Center in Bonn confirmed that each specimen used further for extraction of nucleic acids 
and immunohistochemical staining consisted of at least 80% tumor cells. To avoid a 
possible tumor infiltration, human normal cerebellar tissues were used as a control. Tumors 
were graded according to the World Health Organization (WHO) classification of tumors of 
the central nervous system (Louis et al., 2007) into the following groups: diffuse 
astrocytoma (AII), anaplastic astrocytoma (AAIII), primary glioblastoma multiforme 
(pGBM), and secondary glioblastoma multiforme (sGBM) (Fig. 1.1.2-1). All patients 
agreed to preform molecular analysis on their samples. Specimens were treated in an 
anonymous manner approved by the ethics committee at the University of Bonn.  
 
Table 4.3-1. Investigated human tissues 
 
diagnosis WHO grade no. of patients 
   
diffuse astrocytoma  II 11 
anaplastic astrocytoma  III 22 
primary glioblastoma multiforme  IV 28 
secondary glioblastoma multiforme  IV 8 
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4.4 Extraction of nucleic acids for methylation and fragment analysis studies 
Extraction of DNA and RNA for methylation and fragment analysis was carried out using 
ultracentrifugation of homogenized tumor tissue through a CsCl gradient. Extraction was 
performed by Johannes Freihoff (Institute of Neuropathology, University of Bonn) 
according to instructions described before by Ichimura et al. (1996). 
 
4.5 Methylation of CPEB1-4 genes 
4.5.1 Bisulfite conversion 
DNA methylation occurs on cytosine residues in regions with a high content of CpG 
dinucleotides known as CpG islands. The methylation status of CpG islands of CPEB1-4 
genes was determined by bisulfite conversion according to instructions provided in the 
EpiTect Fast DNA Bisulfite Conversion Kit (Qiagen, Hilden). The bisulfite reaction 
consists of steps necessary for DNA denaturation, subsequent sulfonation and cytosine 
deamination. Isolated DNA samples were incubated with high bisulfite salt concentrations 
at high temperature and low pH to convert unmethylated cytosine residues into uracyl. 
Methylated cytosines remained unchanged. Afterwards converted single-stranded DNA 
was purified on MinElute DNA columns. Membrane-bound DNA was washed with 500 μl 
of washing buffer and desulfonated by incubation for 15 min with 500 μl of desulfonation 
buffer. Next, DNA was washed again with 500 μl of washing buffer to remove the 
desulfonation agent and eluted with 15 μl of elution buffer. Finally, bisulfite converted 
DNA was amplified in PCR reaction and sequenced. 
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Table 4.5.1-1. Analyzed samples 
 
no. of glioblastoma cell lines: 5 
no. of reference tissues: 3-6 
no. of glioma specimens: 63 
 AAIII 12 
 SGBM 10 
 pGBM 41 
 
Table 4.5.1-2. Bisulfite conversion reaction and program 
 
reagent amount 
DNA template 5 μl 
ddH2O 15 μl 
bisulfate solution 85 μl 
DNA protection solution 35 μl 
total volume: 140 μl 
 
 
denaturation 95°C 5 min 
incubation 60°C 10 min 
denaturation 95°C 5 min 
incubation 60°C 10 min 
hold 20°C ∞ 
 
 
Table 4.5.1-3. Bisulfite-DNA amplification PCR reaction and program 
 
reagent amount 
bisulfite - DNA 3 μl 
master mix 12.5 μl 
coral load 2.5 μl 
 forward primer  1.5 μl 
 reverse primer  1.5 μl 
ddH2O 4 μl 
total volume: 25 μl 
 
 
initial 
denaturation 
95°C 15 min  
denaturation 94°C 30 sec 
45x annealing 56°C 30 sec 
extension 72°C 30 sec 
final extension 72°C 10 min  
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4.5.2 Pyrosequencing  
Pyrosequencing of the PCR products containing methylation sites was performed using 
pyrosequencing primers and the PyroMarkGold Reagents (Qiagen, Hilden). 20 μl of each 
bisulfite converted PCR product was pipetted into fresh 96-well reaction plates, 
complemented by 20 μl mastermix and placed on a shaker to maintain dispersion of beads. 
The mastermix composed of 1.5 μl streptavidin-sepharose beads and 18.5 μl binding buffer. 
Afterwards, 1 μl of pyrosequencing primers mixed with 24 μl of annealing buffer was 
pipetted into the fresh pyrosequencing annealing plate. With the use of a vacuum prep tool 
all DNA-beads samples were uniformly sucked from the plate. Attached samples were 
transferred into the 70% ethanol, denaturation solution, washing buffer and beads were 
released into the already prepared annealing plate. The pyrosequencing plate was incubated 
at 80°C for 2 min, cooled down and placed in the sequencing Pyromark Q24 instrument 
(Qiagen, Hilden). Additional cartridge containing PyroMark enzyme, substrate and 
nucleotides were attached to the sequencing instrument. Bisulfite conversion and 
pyrosequencing were performed by Jennifer Hammes (Institute of Neuropathology, 
University of Bonn). 
 
4.5.3 Data analysis 
Pyrogram outputs were analyzed using the PyroMark Q24 software (Qiagen, Hilden). 
Values obtained by CpG-islands pyrosequencing of individual tumor and normal brain 
sample were averaged and compared between each other. Normal brain tissues of age-
matched patients were considered as controls. As a cut-off level for methylation the three 
fold the standard deviation of mean methylation of normal brain samples was chosen. 
Ultimately, values obtained by pyrosequencing were imported into MultiExperiment 
Viewer and visualized as a heat map. 
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4.6 Fragment analysis of CPEB1-4 alternative splice isoforms 
4.6.1 Fragment analysis 
Identification of CPEB1-4 alternative splice variants was performed using RT-PCR 
products with primers spanning previously defined splice variants. CPEB1-4 cDNA was 
amplified by Platinum Taq DNA Polymerase and CPEB primers. One of each primer pairs 
was labeled with a specific fluorescent dye allowing sensitive detection and sizing of the 
PCR products. CPEB splice forms were estimated by electrophoretic separation of 
fluorescently labeled PCR products. Fragment sequencing was performed on thin 
capillaries allowing for distinction of 1bp differences. 
 
Table 4.6.1-1. Analyzed samples 
 
no. of glioblastoma cell lines: 5 
no. of reference tissues: 4 
no. of glioma specimens: 58 
 AII 1 
 AAIII 12 
 SGBM 8 
 pGBM 37 
 
Table 4.6.1-2. PlatinumTaq reaction and PCR program 
 
reagent amount 
ddH2O 13.7 μl 
MgCl2 0.8 μl 
dNTP 0.4 μl 
5x First-Strand Buffer  2 μl 
forward primer 1 μl 
reverse primer 1 μl 
PlatinumTaq DNA polymerase 0.1 μl 
cDNA template in ddH2O 1 μl 
total volume: 20 μl 
 
 
initial 
denaturation 
95°C 15 min 
 
denaturation 95°C 45 sec 
40x annealing 54°C 45 sec 
extension 72°C 45 sec 
final extension 72°C 10 min  
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4.6.2 Data analysis 
RT-PCR products were generated in separate PCR reactions optimized for the individual 
CPEB and diluted to adjust optimal signal strength. Next, fluorescently labeled PCR 
products were pooled and loaded for each individual tumor specimen or cell line. Detection 
and separation of PCR products was performed on an automated DNA sequencing machine 
3130 (Applied Biosystems, Foster City). Electropherogarams of the individual samples 
were analyzed using GeneMapper v3.7 software by reading out the length of the RT-PCR 
product given in base pairs and the signal intensity expressed in relative fluorescent unit, 
which was proportional to the amount of generated PCR product. The fragment analysis 
was performed by Jennifer Hammes (Institute of Neuropathology, University of Bonn). 
 
4.7 Generation of custom-made antibodies  
Custom-made rabbit polyclonal antibodies were raised against CPEB1, CPEB2, CPEB4 
and the phosphorylated form of CPEB3a/c (phospho-CPEB3). Peptide antigens 
(Kaczmarczyk et al., 2016; Turimella et al., 2015) were based on antigenic index (Jameson 
and Wolf, 1988), hydrophobicity (Kyte and Doolittle, 1982) and surface probability (Emini 
et al., 1985) and generated by Eurogentec GmbH (Cologne, Germany). As a carrier protein 
the keyhole limpet hemocyanin was used. For every CPEB two specific pathogen-free 
(SPF) rabbits were injected 4 times with 200 μg of each peptide, in 2-week intervals. Three 
months after the first immunization animals were sacrificed, bled and antibodies were 
purified by affinity purification. The phospho-CPEB3 antibody was directed against a 
region surrounding the S419 and S420 serine residues. The RRGRSSLFPFEDC peptide 
was chosen for immunization and cross-affinity purification of antibody. Purified 
antibodies were directed to mouse as well as human CPEBs. Their specificity was tested by 
peptide competition assay and immunoblot analysis (Kaczmarczyk et al., 2016; Turimella 
et al., 2015). Antibodies bound specifically and did not cross-react with other CPEBs.  
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4.8 Immunohistochemistry  
4.8.1 Staining of paraformaldehyde fixed tissues 
4.8.1.1 Tissue preparation  
Juvenile (p12) or adult (p90) C57Bl6J mice and juvenile (p12) Thy1-GFP mice (Feng et al., 
2000) were perfused via the vascular system using 4% paraformaldehyde (PFA). Next, 
isolated brains were fixed for 24 h in 4% PFA at 4°C and transferred to phosphate buffered 
saline (PBS). Coronal sections of 40 μm thicknesses were prepared on a VT1000S 
vibratome (Leica, Nussloch) and stored in 0.01% NaN3 in PBS at 4°C. 
 
4.8.1.2 Immunohistochemical staining 
Brain sections were washed three times for 10 min with PBS and blocked for 2 h in 10% of 
normal goat serum (NGS), 0.4% Triton X-100 in PBS. Following blocking, sections were 
incubated with the custom-made CPEB2 antibody– (1:50) and GFP– (1:500), MAP2– 
(1:100), PARV– (1:250) or TYH– (1:500) antibodies in 5% of NGS, 0.1% Triton X-100 in 
PBS for 48 h at 4°C. Afterwards, sections were washed with PBS and incubated for 90 min 
with secondary Alexa Fluor antibody– (1:500). Cell nuclei were stained with Hoechst for 
10 min. Then sections were washed with PBS and mounted in Permafluor (Thermo 
Scientific, Runcorn).  
 
4.8.1.3 Microscopy and data analysis 
Images were taken with an Axio Imager Z1 fluorescence microscope (Carl Zeiss GmbH, 
Jena). For quantitative assessment of CPEB2 expression in excitatory, inhibitory, and 
dopaminergic neurons, GFP-parvalbumin-tyrosine hydroxylase-positive cells colocalizing 
with CPEB2 were counted (7-5 slices from three animals per type of neurons).  
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4.8.2 Staining of formalin fixed paraffin-embedded tissues 
4.8.2.1 Generation of tissue microarrays  
The tissue microarray technique allows for simultaneous analysis of multiple histological 
specimens assembled on one glass slide. Here, dissected glioma tissues were fixed with 4% 
PFA for 24–48 h at 4°C and embedded in a paraffin block. Microarrays were prepared by 
taking core needle biopsies from separate paraffin tissue blocks and re-embedding these 
tissues in an arrayed master block on Advanced Tissue Arrayer (Chemicon, Rolling 
Meadows). Afterwards, 4 μm thick tissue sections were prepared in the Lab Vision PT 
Modul (Thermo Scientific, Fremont) followed by pretreatment for 20 min at 99°C in PT 
Modul Buffer (Medac, Hamburg) and a 20 min cool-down phase at room temperature. 
Tissue microarrays were prepared by Brigitte Söndgen (Institute of Neuropathology, 
University of Bonn). 
 
Table 4.8.2.1-1. Analyzed glioma samples 
 
no. of specimens: 69 
 AII 11 
 AAIII 22 
 SGBM 8 
 pGBM 28 
 
 
4.8.2.2 Immunohistochemical staining 
Immunohistochemical staining was performed with a CSA II Biotin-free Tyramide Signal 
Amplification System (Dako, Carpinteria). Endogenous peroxidase activity forming high 
non-specific background staining was eliminated by pretreatment of tissue with hydrogen 
peroxide. Five min peroxidase blocking was followed by 60 min protein block prior to 
incubation of primary antibody. Next, specimens were incubated overnight at 4°C with the 
following antibodies: GFAP– (1:1000), CPEB1– (1:100), CPEB2– (1:250), CPEB3– 
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(1:100), phospho-CPEB3– (1:50), CPEB4– (1:250), phospho- CaMKII– (1:1000) and 
PKA– (1:500). Afterwards sections were treated for 1h with poly-HRP-goat anti-mouse or 
anti-rabbit secondary antibody. Generated signal was enhanced with amplification reagent, 
anti-fluorescein-HRP and 3,3’-diaminobenzidine (DAB), 15 min each. Cell nuclei were 
stained with hematoxylin.  
 
4.8.2.3 Microscopy and data analysis 
Histological evaluation was performed by microscopic observation and digital scan of 
stained specimens. Stainings were observed with an Olympus BX53 research microscope 
(Olympus, Tokyo) and scanned by a Mirax Slide Scanner (Carl Zeiss GmbH, Jena). Tissues 
were categorized as positive or negative for the individual antibody by Dr. Gerritt Gielen 
(Institute of Neuropathology, University of Bonn). Specimens classified as a positive were 
further divided into three intensity groups: weak, intermediate and strong. 
 
4.9 Transfection and stimulation of cultured cells 
4.9.1 Transfection of cultured cells 
Cells were seeded in 6-well plates, grown in complete mouse embryonic fibroblast (MEF) 
culture medium and transfected when ~75% confluency was obtained. One hour prior to 
transfection MEF medium was replaced by trans-MEF cell culture medium with reduced 
serum (2%). The transfection reaction was prepared in 250 μl of opti-MEM with 2 μg of 
expression plasmid and 3 μl of lipofectamine reagent. Transfected cells were incubated for 
5h at 37°C, 5% CO2 and trans-MEF medium was replaced by fresh MEF medium. 
Afterwards cells were incubated for another 48 h and collected for RNA and protein 
analysis. 
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4.9.2 HEK-293FT cells stimulation with forskolin 
In order to test phosphorylation of CPEB3 protein, HEK-293FT cells were transiently 
transfected with CPEB3a-EGFP, CPEB3KD-EGFP and CPEB3b-EGFP constructs. 24 h 
post transfection cells were stimulated for 1 h with 200 μM forskolin, which increases the 
intracellular cAMP concentration and activates cAMP-dependent protein kinase (PKA). 
Control cells were treated with the same amount of dimethyl sulfoxide (DMSO). Following 
forskolin treatment cells were washed with ice-cold PBS and collected for protein analysis. 
 
4.10 Immunocytochemistry  
4.10.1 Coating slides with poly-L-lysine 
Glass coverslips were coated with poly-L-lysine to enhance cell attachment. An aliquot of 
500 μl poly-L-lysine (2 mg/ml) was diluted in 50 ml ddH2O and incubated with coverslips 
for 2h at 37° C. Afterwards coverslips were washed with ddH2O and dried. 
 
4.10.2 Immunocytochemical staining  
Glioblastoma A172 cells were seeded and grown on glass coverslips until obtaining 
approximately 80% of confluency. Next, cells were washed with PBS and fixed for 20 min 
with 4% sucrose in 4% PFA. Cell membranes were permeabilized with 0.5% Triton X-100 
and blocked for 60 min with 10% NGS and 0.5% Triton X-100 at room temperature. 
Following blocking of unspecific binding, cells were stained overnight at 4°C with 
polyclonal antibodies directed to CPEB1-4. Primary antibodies were diluted in PBS 
supplemented with 5% NGS and 0.1% Triton X-100 at the following dilutions: CPEB1– 
(1:100), CPEB2– (1:250), CPEB3– (1:100), phospho-CPEB3– (1:50), CPEB4– (1:250). 
Afterwards, cells were washed with PBS and incubated for 60 min with Alexa secondary 
antibodies (Invitrogen, Rockford). Counterstaining was performed with DAPI dye (Sigma, 
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Saint Louis). Coverslips were mounted using the PermaFluor mounting medium (Thermo 
Scientific, Fremont).  
 
4.10.3 Microscopy and data analysis 
Images were taken with the Zeiss Axio Imager Z1 fluorescence microscope. For qualitative 
estimation of endogenous CPEB1-4 and phospho-CPEB3 expression, human glioblastoma 
A172 cells stained with individual CPEBs were compared to their expression pattern in 
human glioma tissues. 
 
4.11 Extraction of RNA for semi-quantitative real time PCR 
Isolation of RNA from glioblastoma cultured cells was carried out using the RNeasy Mini 
Kit (Qiagen, Hilden). Cells transfected with the CPEB1- pCMV6Neo, CPEB2- pCMV6Neo 
or pCMV6Neo vector were washed with ice-cold PBS and directly lysed with 350 μl of 
RLT buffer (Qiagen, Hilden) supplemented with 1% β-mercaptoethanol (β-ME). Samples 
were frozen in -20°C or the isolation procedure was immediately continued following the 
manufacturer’s protocol.  
 
4.12 Semi-quantitative real time PCR 
4.12.1 Reverse transcription 
1 μg of template RNA was reversely transcribed with SuperScript III reverse transcriptase. 
Isolated RNAs were mixed with 10 mM dNTPs, 50 mM MgCl2, 0.1M DTT and 250 ng of 
random hexamers in a total of 20 μl reaction volume and transcribed to cDNA by reverse 
transcription PCR. 
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Table 4.12.1-1. Reverse transcription reaction and PCR program 
 
reagent amount 
dNTP 1 μl 
Random Hexamer Primer 1 μl 
5x First-Strand Buffer  2 μl 
MgCl2 2 μl 
DTT 2 μl 
SuperScript III reverse transcriptase 0.25 μl 
ddH2O 1.75 μl 
1 μg/μL RNA template in ddH2O 10 μl 
total volume: 20 μl 
 
 
annealing 25 ° C 10 min 
extension 42 ° C 50 min 
reverse 
transcriptase 
inactivation 
70 ° C 15 min 
hold 4 ° C ∞ 
 
 
4.12.2 Semi-quantitative real time PCR 
Semi-quantitative assessment was achieved by amplification of 1 μl cDNA with 900 nM of 
CPEB and PBGD primers, 100 nM of fluorogenic Taqman probes and TaqMan Universal 
PCR Master Mix (Applied Biosystems, Warrington). Probes consisted of a 6-FAM 
fluorophore attached to the 5’-end of oligonucleotide and 3’-end attached the TAMRA 
quencher. The final TaqMan reaction volume was 12.5 μl. 
 
Table 4.12.2-1. TaqMan sqRT-PCR reaction and PCR program 
 
reagent amount 
TaqMan Universal PCR Master 
Mix 
6.25 μl 
TaqMan Assay forward primer 1.125 μl 
TaqMan Assay reverse primers 1.125 μl 
TaqMan Assay probe 0.25 μl 
ddH2O 2.75 μl 
template cDNA 1 μl 
total volume: 12.5 μl 
 
 
UNG activation 50°C 2 min  
initial 
denaturation 
95°C 10 min  
denaturation 95°C 15 sec 
40x annealing and 
extension 
60°C 60 sec 
 
UNG (Uracil‐N glycosylase ) 
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4.12.3 Data analysis  
The critical threshold cycle (CT) value for each reaction was determined using SDS 5.0 
Software (Applied Biosystems, Warrington). Normalization was performed using the 
housekeeping porphobilinogen deaminase (PBGD) gene as a reference against the 
expression of CPEB genes transcripts. The transcript level of CPEB1 and PBGD genes was 
calculated using the following equation: XCPEB/XPBGD = 2
CT PBGD – CT CPEB
, where X is the 
respective input copy numbers and CT is the threshold cycle numbers for CPEB1 and 
PBGD (Seifert and Steinhäuser, 2007). 
 
4.13 Western blotting 
4.13.1 Tissue and cell culture lysates 
Tissue and culture cells were lysate with modified RIPA buffer supplemented with a 
phosphatase and protease inhibitor cocktail. Tissue was homogenized in a 1.5 ml tube with 
a pestle, whereas cells were scraped in cold lysis buffer. Samples were disrupted with a 
27G needle, then sonicated for 10 min and incubated for 30 min on ice. Afterwards cells 
were centrifuged for 15 min at 4°C, 14.000 g and their supernatants were collected for the 
further analysis. Total protein content was estimated by a BCA protein assay. For this 
purpose 25 μl of protein standard (20-2000 μg/ml range; Thermo Scientific, Rockford) and 
5 μl of lysate mixed with 20 μl ddH2O was pipetted into a 96-well plate. The plate was 
gently shaken for 25 min at 37°C. Colorimetric detection and quantitation of total protein 
concentration was performed with an OptiMax Tunable Microplate Reader (Molecular 
Devices, Sunnyvale). 
 
4.13.2 SDS-PAGE and Western blotting 
30 µg of protein samples were mixed with denaturing sample buffer and heated for 5 min at 
95°C. Next proteins were separated according to their molecular weight by SDS-PAGE (30 
Methods 
 
73 
 
min at 80 V, 0.04 mA followed by 1.5h at 220 V, 0.06 mA) and blotted (2h at 100 V) on a 
PVDF membrane (GE Healthcare Life Sciences, Buckinghamshire). Afterwards, 
membranes with transferred non-phosphorylated proteins were blocked for 1h in 5% milk 
powder in T-BST and membranes with transferred phosphorylated proteins in 3% BSA in 
T-BST. Then membranes were incubated overnight with primary antibodies suspended in 
2.5% milk powder (non-phosphorylated antibodies) or 2% BSA (phosphorylated 
antibodies) in T-BST. The next day membranes were washed with TBS-T buffer, incubated 
for 1h with horseradish peroxidase (HRP) secondary antibody in 2.5% milk powder in T-
BST and visualized. 
 
4.13.3 Data analysis 
HRP activity was detected with Supersignal West Dura Substrate (Thermo Scientific, 
Rockford). Generated chemiluminescence was measured with the Gene Genome digital 
documentation system (Synoptics, Cambridge). Densitometry was performed with 
GeneTools System (Synoptics, Cambridge) and tested for significant differences.  
 
4.14 Measurement of cellular proliferation and viability  
4.14.1 FACS samples preparation 
The dis-regulation of CPEB expression observed in glioma was the reason to study their 
influence on growth properties and apoptotic activity in in vitro conditions. Glioblastoma 
cells were transiently transfected with CPEB1-pCMV6Neo, CPEB2-pCMV6Neo or control 
pCMV6/Neo vector and subsequently their expression was monitored by sqRT-PCR and 
Western blot. Here, cells were additionally co-transfected with pmaxGFP to allow detection 
of CPEB-GFP positive cells by fluorescence-activated cell sorting (FACS). 24 h post 
transfection MEF medium was replaced with serum-starved MEF medium to induce 
apoptosis. The next day attached and detached cells of the flask were collected, washed 
with ice-cold PBS and transferred to the FACS tubes (polystyrene, non-pyrogenic). Cells 
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were fixed for 10 min in 4% PFA, permeabilized for 5 min in 0.5% Triton X-100 and 
stained. Proliferating cells were labeled with an Alexa Fluor 647-labeled antibody against 
phospho-(ser10)-histone H3 (pHH3; 1:20), whereas apoptotic cells were stained with a 
phycoerythrin-labeled antibody recognizing cleaved poly(ADP-ribose) polymerase (PARP; 
1:5). Incubation with antibody for 30 min at room temperature was followed by 30 min 
DAPI staining (10 μg/ml) at 37°C.  
 
4.14.2 Proliferation and viability analysis 
Samples were analyzed with the use of BD FACS Canto II digital benchtop analyzer (BD 
Biosciences, Heidelberg). In each experiment at least 100000 GFP- CPEB1-pCMV6/Neo, 
GFP- CPEB2-pCMV6/Neo, GFP- pCMV6/Neo or pmaxGFP positive single cells were 
analyzed. Cells transfected with GFP- pCMV6/Neo or pmaxGFP vector were considered as 
reference samples. Non-transfected cells labeled only with pHH3 antibody or stimulated for 
24 h with 1 μM staurosporine and stained with PARP antibody were used as a control to 
monitor proliferation and apoptosis, respectively. 
 
4.15 Measurement of cellular migration 
4.15.1 In vitro scratch assay 
Migration of cultured glioblastoma cells transiently overexpressing CPEB1 and CPEB2 
proteins was tested by an in vitro wound healing assay. A reproducible size scratch was 
created by the tip of a glass pipet on a confluent cell monolayer in the center of culture 
dish. Cell motility was monitored for 24 h. 
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4.15.2 Cell migration analysis  
The motility of CEPB overexpressing cells was measured by the area covered by cells over 
time. 24 h after the scratch cells migrated into the center of the wound, which was imaged 
and quantified. 
 
4.16 Cancer associated pathway activity assay 
4.16.1 Reverse transfection 
A pathway reporter array allowed for simultaneous analysis of 45 cancer-associated 
signaling pathways by screening their activities. Quantitative assessment was possible upon 
overexpression of CPEB1-pCMV6/Neo, CPEB2-pCMV6/Neo and control pCMV6/Neo 
plasmids in cultured cells and its reverse transfection with reporter constructs from array 
plates. Every construct was assembled of a constitutively expressed Renilla reporter and an 
inducible transcription factor responsive firefly luciferase reporter. Positive control was 
composed of a mixture of a constitutively expressed firefly luciferase and Renilla luciferase 
GFP constructs. Negative control was composed of non-inducible firefly luciferase reporter 
and constitutively expressed Renilla reporter. Reverse transfection was initiated by 
activation of reporter constructs from array plates by adding 50 μl of Opti-MEM. For each 
transfection reaction 0.3 μl lipofectamine in 50 μl of Opti-MEM was used. The mixture was 
added onto the plate, gently mixed and incubated for 20 min. A172 cells transiently 
expressing CPEB1-pCMV6/Neo, CPEB2-pCMV6/Neo and control pCMV6/Neo plasmids 
were washed with PBS without Ca
2+
 and Mg
2+
, trypsinized, suspended in Opti-MEM with 
5% FBS and counted. 15.000 cells per well in 50 μl of Opti-MEM with 10% FBS and 1% 
NEAA was added into each well and incubated for 24 h at 37°C. Afterwards the medium 
was replaced with MEF growth medium, incubated for another 24 h at 37°C and signals 
were detected by a dual-luciferase assay. 
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4.16.2 Dual-luciferase reporter assay  
A dual luciferase assay was performed 48 h after reverse transfection. Grown medium was 
removed from cultures cells, cells were rinsed with PBS and 10 μl of PLB was added into 
each well of Cignal 45-Pathway Reporter Array plates. After 15 min of gentle shaking at 
room temperature firefly (Photinus pyralis) and Renilla (Renilla reniformis) luciferases 
activities were measured sequentially from each well. First the firefly luciferase reporter 
was measured by adding 50 μl of Luciferase Assay Reagent II to generate a stabilized 
luminescent signal. After quantification the firefly luminescence, reaction was quenched, 
and the Renilla luciferase reaction was initiated by 50 μl of Stop & Glo Reagent added to 
the same well. Renilla luciferase signal decayed slowly over the course of the 
measurement. 
 
4.16.3 Cancer associated pathways activity analysis 
Firefly and Renilla luciferase activities were analyzed using GloMax 96 Microplate 
Luminometer. Results were calculated by dividing the normalized luciferase activity of 
each pathway reporter reverse transfected into A172 cells overexpressing CPEB1-
pCMV6/Neo or CPEB2-pCMV6/Neo plasmid by the normalized activity of pathway 
reporter transfected with the control pCMV6/Neo vector. Reporters showing minimum 
two-fold change of relative luciferase units were considered as up- or downregulated. 
Experiments repeated three times in duplicates were further tested for statistical 
significance using OrigeneLab Corporation software (Northampton, MA, USA). 
 
4.17 Statistics 
In chapters 5.1.1, 5.1.4 and 5.2.2, the subsequent statistical analysis was conducted. Each 
data set was tested for Gaussian distribution by the Shapiro-Wilk-test. Next, for the 
comparison of two independent variables the normally distributed data was further 
examined with the F-test for equivalence of variances. Accordingly, Student’s t-Test 
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without or with Welsh correction was performed. For comparison of more than two 
independent variables one-way ANOVA with post-hoc Tukey-test was applied. Therefore, 
the data were tested for equal variances by the Levene-test and based on the result Welsh-
correction was performed. Non-normal distributed data were analyzed with non-parametric 
tests. Therefore, data sets with two independent variables were tested with Mann-Whitney 
U test and sets with three or more independent variables with the Kruskal-Wallis-ANOVA 
and post-hoc Bonferoni-corrected Mann-Whitney U test. Data are represented as mean ± 
SEM. In chapter 5.1.2, IDH1 mutation was correlated with CPEB1 and CPEB3 methylation 
by Fisher’s two-sided exact test. While, in chapter 5.1.3.2, clinical course of glioma 
patients was correlated with CPEB expression data by Kaplan-Meier survival analysis. 
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5 RESULTS 
 
5.1 Functional analysis of CPEB 1-4 in the pathogenesis of gliomas 
5.1.1 Methylation of CPEB 1-4 genes in the 5’-CpG islands in gliomas  
Methylation of DNA belongs to the heritable alternations in gene function, occurring 
without a change in the DNA sequence. Such epigenetic reaction may have inhibitory 
effects on gene expression. It neither alters nucleotide sequences nor affects the specificity 
of DNA base pairing. Differential methylation hybridization is a commonly used technique 
to identify changes in methylation patterns observed in cancers. Here, the methylation 
status of CPEB1-4 genes was determined by bisulfide treatment and pyrosequencing of 
glioma (n=63), normal brain (n=3-6) and cultured glioblastoma samples (n=5) (Fig. 5.1.1-
1). De novo hypermethylation in the investigated CpG-islands was detected in CPEB1 (Fig. 
5.1.1-1) and the gene was identified as a target for epigenetic inactivation in gliomas. In 
normal brain specimens of age-matched patients only trace methylation of up to 16% was 
observed (Fig. 5.1.1-2). The methylation cut-off was set to three-fold the standard deviation 
of the mean of normal brain samples (n=6; threshold methylation of 13.12%). CPEB1 
methylation was detected in most of the AAIII (9/11; mean methylation of 62.31 ± 2.93%), 
and sGBM specimens (10/10; mean methylation of 55.40 ± 8.79%) that developed 
following malignant progression of lower-grade precursor lesions (Fig. 5.1.1-1). 
Furthermore, all examined glioblastoma cell lines showed hypermethylation of CPEB1 
(mean methylation of 72.7 ± 4.89%, data not shown). In contrast to CPEB1, methylation of 
CPEB3 was less abundant (mean methylation of 10.19 ± 0.43%). In the cohort of 
investigated samples only a few pGBM cases showed an increased methylation up to 
19.09% (Fig. 5.1.1-1). CPEB2 and CPEB4 did not demonstrate methylation of CpG-islands 
in any of the investigated tumors. This is indicated by a blue color on the heat map, which 
corresponds to the lack of methylation (Fig. 5.1.1-1). 
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Figure 5.1.1-1. 
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Figure 5.1.1-2. 
 
Figure 5.1.1-1. Methylation profile of CPEB1-4 genes in glioma and normal brain tissues. Bars above the 
heat maps indicate the methylation in % (range 0-50 for CPEB1; range 0-20 for CPEB2-4). Columns show 
investigated CpG dinucleotides, while rows present the individual glioma and control tissue samples. Blue 
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color corresponds to the lack of methylation, while red indicates increase in methylation of investigated 
tumors. 
 
Figure 5.1.1-2. Pyrosequencing analysis of the CpG island in the 5’-region of CPEB1 gene in sGBM, 
pGBM and normal brain tissue. The pyrogram of a sGBM (A) shows a strong methylation of up to 83% of 
the CpG positions. The pyrograms of a pGBM (B) and the normal brain tissue (C) show methylation of the 
investigated region up to 16%. 
 
5.1.2 IDH1 mutation in gliomas 
Mutation of IDH1 gene occurs frequently in low-grade and secondary high-grade gliomas. 
IDH mutations drive increased methylation of DNA and are associated with improved 
prognosis for patients (Cohen et al., 2013). In the investigated cohort of gliomas, 1/1 AII, 
9/11 AAIII, 7/10 sGBM and 4/41 pGBM revealed mutation in the IDH1 gene. Secondary 
GBM tumors with mutated IDH1 (n=7) demonstrated an average methylation of 69.37 ± 
6.78%. Surprisingly, few pGBM samples with mutated IDH1 (n=4) also disclosed a 
significant increase of CPEB1 methylation (mean 73.53 ± 4.26%). Secondary GBMs 
without IDH1 mutation (n=3) and pGBMs with wild type IDH1 (n=37) showed an average 
methylation of 21.81 ± 8.93% and 19.84 ± 2.74% in the investigated region of CPEB1 
(Tab. 5.2.2-1). The described pattern indicates that IDH1 mutation, are tightly linked to the 
CPEB1 methylation status. CPEB1 belongs to the methylation targets affected by the 
glioma associated CpG island methylator phenotype (G-CIMP) in IDH1 mutant gliomas. In 
contrast to CPEB1, no correlation was observed between CPEB3 methylation and IDH1 
mutation. 
 
 
 
 
Table 5.1.2-1. Mutation of IDH1 and methylation of CPEB1 in human glioma specimens. 
 
   mean± SEM  mean± SEM 
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IDH1 
mutation 
 
no. of 
investigated 
samples 
 
no. of samples 
with IDH1 
mutation 
 
CPEB1 
methylation [%] 
no. of samples 
without IDH1 
mutation 
 
CPEB1 
methylation [%] 
      
AII 1 1 73.11 0 - 
AAII 11 9 62.31±2.93 2 9.50 
sGBM 10 7 69.37 ± 6.78 3 21.81 ± 8.93 
pGBM 41 4 73.53 ± 4.26 37 19.84 ± 2.74% 
 
 
5.1.3 Expression profile of CPEB 1-4 in gliomas 
5.1.3.1 Expression of CPEB 1-4 in human glioma specimens  
Histological characterization of CPEBs was the next step to understand their role in human 
brain cancer. Glioma specimens assembled on tissue microarrays were stained with custom 
CPEB antibodies and evaluated by microscopic observation and neuropathologic 
assessment (Fig. 5.1.3.1-1; Fig. 5.1.3.1-2; Tab. 5.1.3.1-1). All of the investigated specimens 
were stained with GFAP antibody to confirm their affiliation to the group of astrocytomas. 
CPEB1 was detected in the infiltration areas of tumor cells in normal brain tissue. 
However, the majority of cells in the tumor center, in the areas of angiogenesis and necrosis 
showed no CPEB1 expression (Fig. 5.1.3.1-1). Strong immunoreactivity against CPEB1 
was present only in few (2/61) glioma tissues (Tab. 5.1.3.1-1). Downregulation of CPEB1 
protein was observed with a rising grade of glioma malignancy (Fig. 5.1.3.1-2). The vast 
majority of astrocytoma specimens revealed a positive staining for CPEB1 (26/29: 8/8 
AAII and 18/21 AAIII). 23/32 glioblastoma (6/7 sGBM and 17/25 pGBM) samples 
contained CPEB1 positive cells (Tab. 5.1.3.1-1). CPEB2 was present in reactive astrocytes 
of normal brain tissue and in endothelial cells of vessels residing within the tumor tissue 
(Fig. 5.1.3.1-1). Positive staining was revealed in most of the studied glioma specimens 
(8/9 AAII; 18/20 AAIII; 7/8 sGBM; 18/25 pGBM) (Tab. 5.1.3.1-1). Among CPEBs in 
gliomas, CPEB3 occurred to be the most abundant and widespread in the cytoplasm and 
processes of astrocytic tumor cells (Fig. 5.1.3.1-1). Strong immunoreactivity against 
CPEB3 was detected in 8/10 AAII, 19/20 AAIII, 7/7 sGBM and 23/24 pGBM (Tab. 
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5.1.3.1-1). Enhanced CPEB3 signal was associated with an increased grade of malignancy. 
The opposite trend was observed with a phosphospecific CPEB3 antibody. Here, 
phosphorylation of CPEB3 protein was observed mainly in low-grade gliomas (7/8 AAII; 
17/20 AAIII) and distinctly reduced in glioblastomas (10/26 pGBM) (Tab. 5.1.3.1-1). 
Analogous to CPEB1, strong expression of CPEB4 was found in only few tumors (10/62) 
(Tab. 5.1.3.1-1). Proteins were distributed in tumor cell bodies and processes (Fig. 5.1.3.1-
1). In conclusion, above experiments revealed a distinctive and differential expression 
pattern of individual CPEBs that could be correlated with the glioma malignancy grade. 
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Figure 5.1.3.1-1.  
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Figure 5.1.3.1-2. 
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Figure 5.1.3.1-1. Immunohistochemical analysis of CPEB1-4 protein expression in gliomas. Staining of 
AII (CPEB3) and AA III (CPEB1, CPEB2, and CPEB4) tissues with CPEB1, CPEB2, CPEB3 and CPEB4 
antibodies. The brown areas represent CPEB protein deposits while the blue regions correspond to the cell 
nuclei.  
 
Figure 5.1.3.1-2. Evaluation of CPEB1-4 and phospho-CPEB3 protein expression in glioma tissues. A: 
CPEB1, B: CPEB2, C: CPEB3, D: phospho-CPEB3, E: CPEB4: Light blue graph sections represent the lack 
of CPEB expression, while blue and dark blue sections correspond to the positive CPEB staining divided 
subsequently to intensity groups: weak, intermediate, and strong. 
 
Table 5.1.3.1-1. Quantification of CPEB1-4 and phospho-CPEB3 expression in human glioma specimens. 
Table contains number of not accessible and investigated specimens assembled on tissue microarrays. 
 
CPEB1 expression 
no. of not 
accessible 
samples 
no. of 
investigated 
samples 
no. of 
negative 
samples 
no. of positive  
samples- 
weak 
intensity  
no. of positive  
samples-
intermediate 
intensity  
no. of positive  
samples-
strong 
intensity  
       
AII 3 8 0 3 4 1 
AAII 1 21 3 8 9 1 
sGBM 1 7 1 4 2 0 
pGBM 3 25 8 12 5 0 
sum: 8 61 12 27 20 2 
percentage:  100% 19.67% 44.26% 32.79% 3.28% 
       
CPEB2 expression  
AII 2 9 1 2 2 4 
AAII 2 20 2 9 4 5 
sGBM 0 8 1 1 4 2 
pGBM 3 25 7 10 6 2 
sum: 7 62 11 22 16 13 
percentage:  100% 17.74% 35.48% 25.81% 20.97% 
       
CPEB3 expression  
AII 1 10 2 3 3 2 
AAII 2 20 1 8 9 2 
sGBM 1 7 0 0 3 4 
pGBM 4 24 1 6 12 5 
sum: 8 61 4 17 27 13 
percentage:  100% 6.56% 27.87% 44.26% 21.31% 
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phospho-CPEB3 
expression 
no. of not 
accessible 
samples 
no. of 
investigated 
samples 
no. of 
negative 
samples 
no. of positive  
samples- 
weak 
intensity  
no. of 
positive  
samples-
intermediate 
intensity  
no. of 
positive  
samples-
strong 
intensity  
       
AII 3 8 1 2 3 2 
AAII 2 20 3 10 6 1 
sGBM 0 8 1 7 0 0 
pGBM 2 26 16 10 0 0 
sum: 7 62 21 29 9 3 
percentage:  100% 33.87% 46.77% 14.52% 4.84% 
       
CPEB4 expression  
AII 1 10 0 6 3 1 
AAII 2 20 0 12 5 3 
sGBM 1 7 1 1 4 1 
pGBM 3 25 4 11 5 5 
sum: 7 62 5 30 17 10 
percentage:  100% 8.06% 48.39% 27.42% 16.13% 
 
 
5.1.3.2 Correlation of CPEB 1-4 expression with clinical prognosis of glioma patients 
Clinical course of glioma patients was correlated with CPEB expression data by Kaplan-
Meier survival analysis. Overall survival was determined as a time between surgery of 
primary tumor and death of the patient. When the expression of CPEB1 protein in all 
investigated samples (n=61) was compared with patients survival no correlation was 
detected (Fig. 5.1.3.2-1A). Nevertheless, if the studied group was narrowed to only low-
grade astrocytoma samples (n=29), the Kaplan-Meier curve suggested a positive correlation 
between CPEB1 expression and longer patient survival (Fig. 5.1.3.2-1B). The remaining 
pGBM (17/25) and sGBM (6/7) specimens expressing CPEB1 protein did not reveal any 
significant relation with the life expectancy of patients. Despite a robust expression, neither 
CPEB2-3 nor CPEB4 showed correlation with survival of glioma patients (Fig. 5.1.3.2-1C, 
D, G). CPEB3 activation, as determined by phosphorylation was significantly correlated 
with longer patient survival in all investigated tumor samples (n=62) (Fig. 5.1.3.2-1E). 
Interestingly, in the analysis focused on low-grade astrocytomas (n=28), which are 
considered precursor lesions for sGBM and show a molecular pathology distinct from 
pGBM, a significant correlation between CPEB3 activity and prolonged patient survival 
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was observed (Fig. 5.1.3.2-1F). It indicates that phospho-CPEB3 protein might be a novel 
biological marker for a better prognosis of low-grade glioma patients. However, it may be 
also considered as a marker of glioma patients independently of histological entity or 
grading.  
 
 
Results 
 
92 
 
 
 
Figure 5.1.3.2-1. Correlations between expression of CPEB 1-4 and survival of glioma patients. A: 
Kaplan- Meier survival analysis showed no correlation between CPEB1 expression and longer survival in all 
investigated glioma patients B: Positive correlation between CPEB1 expression and patient survival was 
observed in a subpopulation of AAII and AAIII. C, D, G: No correlation was observed between CPEB2, 
CPEB3 and CPEB4 expression and patient survival. E: Significant correlation between phospho-CPEB3 
expression and survival data was observed in all investigated glioma samples. F: Detail studies on AAII and 
AAIII (n=28) as well as primary (n=26) and secondary (n=8) GBM samples indicated that phospho-CPEB3 
expression when compared to survival reach statistical significance only in the group of AAII and AAIII. 
 
5.1.4 CPEB1 gene methylation and its influence on expression profile. 
The current study on expression of CPEBs in gliomas revealed an interesting dependency 
between tumor malignancy grade and the change in their expression level. In parallel to the 
increasing grade of glioma, expression of CPEB1 protein decreased (Fig. 5.1.3.1-2; Tab. 
5.1.3.1-1). The observed effect was verified by sqRT-PCR transcript analysis in glioma 
(n=25) and reference normal brain (n=6) samples. Investigated specimens contained 
significantly reduced transcript level, as compared to the control tissue. In particular, 
CPEB1 expression was decreased by 37% in AAIII (n=6), 6 % and 9 % in sGBM (n=3) and 
pGBM (n=16) (Fig. 5.1.4-1A), respectively. Afterwards, the same set of specimens was 
analyzed for CPEB1 gene methylation. A significant increase in methylation was detected 
in AAIII and sGBM, but not in pGBM, when compared to the control brain samples (Fig. 
5.1.4-1B). As hypermethylation of DNA is considered to have an inhibitory effect on gene 
expression, the correlation between methylation and expression profile of CPEB1 was 
examined performing Pearson's correlation analysis (data not shown). However, despite the 
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strong trend indicating such dependence, CPEB1 methylation and expression were not 
correlated.  
 
  
 
Figure 5.1.4-1. Comparison of CPEB1 methylation and expression in glioma and reference samples. A: 
Significant decrease of CPEB1 transcript was observed with rising grade of tumor malignancy in AAIII, 
sGBM and pGBM samples. B: Significant increase in CPEB1 methylation was observed in AAIII and sGBM, 
but not in pGBM samples. 
 
5.1.5 Activity dependent expression of CPEB3 protein in gliomas 
Evaluation of CPEB3 and the phospho-CPEB3 protein uncovered their differential 
expression patterns in human glioma specimens. In parallel to the rising grade of glioma 
malignancy, expression of CPEB3 increased, while expression of phospho-CPEB3 was 
reduced (Fig. 5.1.3.1-2C, D). To confirm the specificity of phospho-CPEB3 antibody, the 
splice variants of CPEB3a, CPEB3aKD (CPEB3a kinase dead) or CPEB3b were cloned 
into the pEGFP-N1 expression vector and overexpressed in HEK-293FT cells (Fig. 5.1.5-
1). Transfection of CPEB3 plasmids was followed by cell stimulation with 200 μM 
forskolin, which increases the intracellular cAMP concentration and activates PKA. 
Afterwards, expression of CPEB3 variants was quantified by Western blot analysis. The 
full-length CPEB3a isoform was detected by both, CPEB3 and phospho-CPEB3 antibody. 
The effect of forskolin stimulation was observed as an increased intensity bands detected 
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by phosphospecific CPEB3 antibody in CPEB3a overexpressing cells. The CPEB3aKD 
variant contained two serines (S419; S420) in the phosphorylation site, which were mutated 
to alanine. Therefore, despite forskolin treatment, no phosphorylation was observed. 
Similarly, CPEB3b isoform lacking the B-region localized next to putative phosphorylation 
sites for PKA, CaMKII and RPS6K did not reveal any phosphorylation (Fig. 5.1.5-1). This 
finding confirmed that only the CPEB3 isoform comprising both, phosphorylation sites and 
the B-region, could be effectively activated by phosphorylation.  
Next, in order to understand activity dependent CPEB3 expression, CPEB3, phospho-
CPEB3 and kinases indicated before as putative CPEB3 activators, CaMKII and PKA, 
were further examined by immunostaining (Kaczmarczyk et al., 2016; Theis et al., 2003). 
Two groups of tumor samples were investigated. The first group of low-grade astrocytomas 
(n=6; AII and AAIII) was characterized by strong CPEB3 and phospho-CPEB3 expression. 
The second group contained primary GBMs samples (n=7) positive for CPEB3, but 
negative for phospho-CPEB3 antibody (Fig 5.1.5-2). Robust expression of PKA and 
phospho-CaMKII was detected in low-grade astrocytomas, which also contained active 
CPEB3 protein (Fig 5.1.6-1). However, despite the kinases activity in high-grade gliomas, 
the expression of phosphorylated CPEB3 protein was reduced (Fig 5.1.5-2). Therefore, lack 
of active kinases cannot explain the loss of CPEB3 phosphorylation in high-grade gliomas. 
 
 
Figure 5.1.5-1. 
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Figure 5.1.5-2. 
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Figure 5.1.5-1. Immunoblot presenting phosphorylation of CPEB3a-EGFP, CPEB3aKD-EGFP and 
CPEB3b-EGFP isoforms in HEK-293FT cells. Overexpressed CPEB3-EGFP protein was stimulated with 
forskolin to activate PKA. Immunoreactivity against CPEB3 antigene was detected in all investigated splice 
isoforms, while immunoreactivity against phospho-CPEB3 antigene was observed only in the CPEB3a 
variant.  
 
Figure 5.1.5-2. Immunohistochemical analysis of altered CPEB3 activity in low-grade astrocytoma and 
primary GBM specimens. In the upper row of the figure cell nuclei (violet) and cytoplasm (pink) were 
stained by hematoxylin and eosin, respectively. The following lower rows represent brown areas of 
respective: GFAP; CPEB3; phospho-CPEB3; phospho- CaMKII; PKA antibody staining and dark blue areas 
corresponding to cell nuclei stained by hematoxylin. 
 
5.1.6 Alternative splice isoforms of CPEB1-4 in human gliomas 
The presence of multiple alternative splice isoforms of CPEB paralogs uncovered the 
complexity of their regulatory functions. Here, alteration in the abundance of CPEB1-4 
splice variants was studied in primary glioma tissues (n=58), glioblastoma cell lines (n=5), 
and normal brain tissues (n=4) (Tab. 5.1.6-1). The optimized RT-PCR approach allowed 
for the quantitative assessment of CPEB variants by electrophoretic separation of 
fluorescently labeled PCR products. Differences between CPEB splice variants depend on 
presence or absence of respective B- and C-regions. Of particular importance is the B-
region adjacent to the two serine residues (S419; S420), because it is responsible for 
phosphorylation and further activation of CPEBs (Fig. 5.1.6-1).  
In the present study, a significant change in expression of alternative transcripts was 
observed between tumor and reference brain tissues. Most of the investigated AAIII 
specimens contained the same alternative transcripts, while GBMs lost several of the 
CPEB2-4 splice variants as compared to normal brain samples (Fig. 5.1.6-2). In the 
reference tissue the following alternative variants of CPEBs were the most abundant: 
CPEB1Δ5 (169bp); CPEB2a (375bp; full-length isoform), CPEB2c (286bp; lack of C- and 
E-region); CPEB3a (600bp; full-length isoform), CPEB3b (576b; lack of B-region), 
CPEB3c (531bp; lack of C-region), CPEB3d (507bp; lack of B- and C-region); CPEB4a 
(277bp; full-length isoform of CPEB4), CPEB4b (254bp; lack of B-region), CPEB4c 
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(226bp; lack of C-region), CPEB4d (203bp; lack of B- and C-region) (Fig. 5.1.6-2). 
Interestingly, the abundance of CPEB1 seemed not to be altered in gliomas. In all except 
two pGBM samples, which revealed the 182bp CPEB1 splice variant, corresponding to the 
full-length isoform, the only found CPEB1 transcript was 169bp CPEB1Δ5 (Fig. 5.1.6-2; 
Tab. 5.1.6-1). The abundance of the full-length isoforms of CPEB2-4 appeared to be 
reduced and instead the b/d variants, lacking the B-region were expressed. Consequently 
20/37 pGBM and 5/8 sGBM samples were deprived of CPEB2a, 36/37 pGBM and 8/8 
sGBM samples were deprived of CPEB3a and 30/37 pGBM and 6/8 sGBM were deprived 
of CPEB4a as compared to AAIII and reference tissues (Tab. 5.1.6-1). Furthermore, 
11/37pGBM and 3/8 sGBM samples were devoid of the CPEB2c*, while 35/37 pGBM and 
6/8 sGBM samples were devoid of the CPEB4c variant also containing the B-region (Tab. 
5.1.6-1). Additionally, some of the detected CPEB2 isoforms contained the E-region (Tab. 
5.1.6-1; Fig. 5.1.6-1), which was previously described in mouse CPEB2 (Turimella et al., 
2015). 
Differences between splice isoforms were further reflected by properties of the expressed 
proteins, because only CPEB a/c variants containing the B-region were subject to 
phosphorylation. As most of the splice variants missing the B-region were expressed in 
high-grade gliomas, alternative splicing seemed to play an important role in tumor 
progression.  
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Figure 5.1.6-1. 
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Figure 5.1.6-2. 
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Figure 5.1.5-1. Scheme of CPEB1-4 splice variants detected by fragment analysis in normal brain and 
glioma samples. Individual panels contain labeled B, C or E-regions and phosphorylation sites of respective 
CPEB variants. 
 
Figure 5.1.6-2. Relative abundance of respective splice variants of the four CPEB genes revealed by the 
RT-PCR fragment analysis. Values of the x-axis correspond to the fragment length of the RT-PCR product 
given in base pairs. The y-axis defines signal intensity (relative fluorescent units) which is proportional to the 
amount of generated PCR product. The size of the RT-PCR product generated by fragment analysis does not 
describe the actual length of the respective splice product, but length of fragments detected with primers 
spanning previously defined splice variants. 
 
Table 5.1.6-1. The RT-PCR products of specific splice variants of the CPEB1-4 genes detected in AII; 
AAIII, pGBM, sGBM, normal brain tissues and GBM cultured cells. The upper values above the table 
correspond to the RT-PCR product (size in base pairs) generated by fragment analysis. The following 
alternative variants of CPEBs were detected: CPEB1Δ5 (169bp), CPEB1 (182bp); CPEB2d (262bp; lack of 
B, C, E-region) CPEB2d* (271bp; lack of B, C-region), CPEB2c (286bp; lack of C, E-region), CPEB2c* 
(294bp; lack of C-region), CPEB2b (351bp; lack of B-region), CPEB2a (375bp; full-length isoform); 
CPEB3d (507bp; lack of B, C-region), CPEB3c (531bp; lack of C-region), CPEB3b (576b; lack of B-region), 
CPEB3a (600bp; full-length isoform); CPEB4d (203bp; lack of B, C-region), CPEB4c (226bp; lack of C-
region), CPEB4b (254bp; lack of B-region), CPEB4a (277bp; full-length isoform of CPEB4). 
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                         A 
 
CPEB1 Δ5 CPEB1
Diagnose ID-T-Nummer CPEB1 169 bp 182 bp 508 bp 599 bp
AAIII 2377 26683
AAIII 2526 30894
AAIII 2725 21376
AAIII 2744 23806
AAIII 2771 31813
AAIII 2897 37449
AAIII 2899 24278
AAIII 3423 54168
AAIII 3545 28195
AAIII 3546 45194
AAIII 3548 34216
AAIII 4045 32681
pGBM 71 38072
pGBM 72 32832
pGBM 132 27337
pGBM 172 21483
pGBM 327 7186
pGBM 328 25658
pGBM 625 27745
pGBM 862 19256
pGBM 1010 25856
pGBM 1311 30762
pGBM 1619 20905
pGBM 1968 26145
pGBM 2010 34031
pGBM 2104 23173
pGBM 2169 18711
pGBM 2304 25799
pGBM 2481 27551
pGBM 2486 26420
pGBM 2494 30091
pGBM 2735 43101
pGBM 2757 20864
pGBM 2854 30034
pGBM 2884 21244
pGBM 2896 19339
pGBM 3007 52052
pGBM 3031 37154
pGBM 3032 26770
pGBM 3066 7859
pGBM 3070 16581 1909
pGBM 3513 30871
pGBM 3747 36070
GBM oligo 2655 20061
GBM RZ 3527 21366
GBM sark 2643 17833
GBM sark 3555 18439 2160
Normal Brain NBfrontal 17581
Normal Brain NBoccipital 14549
Normal Brain NBparietal 1864
Normal Brain NBtemporal 24982
AII 1418 26306
pGBM LÜ 820 38785
pGBMsark 176 24154
sGBM 677 18769 3412
sGBM 1214 24461
sGBM 1329 39085
sGBM 1430 24163
sGBM 1944 16999
sGBM 2007 43109
sGBM 2727 20646
sGBM 3475 17974
GBM cells A172 38776
GBM cells LN229 20089
GBM cells LN428 27441
GBM cells T98G 23426
GBM cells U178 48217
more abundant in glioma tissue and reduced or lacking in normal brain tissues
Detected splice isoforms:
more abundant in normal brain tissue and reduced or lacking in tumors
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      B 
 
Detected splice isoforms: CPEB2d CPEB2d* CPEB2c CPEB2c* CPEB2b CPEB2a
Diagnose ID-T-Nummer CPEB2 170 bp 203 bp 262 bp 271 bp 286 bp 294 bp 351 bp 375 bp
AAIII 2377 19243 3816 21200 7022 8456
AAIII 2526 15307 28051 4055 4453
AAIII 2725 13604 2454 17950 2852 3193 4612
AAIII 2744 7681 12972 4560
AAIII 2771 8959 1071 13648 1525 1776 2961
AAIII 2897 9514 34779 4853 2798 16075
AAIII 2899 5384 24686 4201 8263
AAIII 3423 9284 23739 2808 6835
AAIII 3545 19103 31827 3676 4930 10797
AAIII 3546 9080 34540 6921 7906
AAIII 3548 12417 23140 2490 3353 7882
AAIII 4045 3934 57221 4731 9744
pGBM 71 15391 2816 5999 1907
pGBM 72 23004 3795 11148 5366
pGBM 132 8845 9613 1354
pGBM 172 16565 15177 5853
pGBM 327 19305 5559 2000
pGBM 328 27750 20949 6870
pGBM 625 28744 3612 10825 7319 3753
pGBM 862 17776 2447 6002 1722
pGBM 1010 15453 2242 9012 1193 3549 2778
pGBM 1311 39092 4376 12895 5148
pGBM 1619 20667 14643
pGBM 1968 22959 18904 6162
pGBM 2010 21862 2844 16371 2312 7560 7230
pGBM 2104 20673 2917 32529 4586 4254
pGBM 2169 33190 4799 10029 4174
pGBM 2304 20938 3913 8495 2218
pGBM 2481 21328 23116 6976
pGBM 2486 23707 19784 3520
pGBM 2494 10869 12771 2577 3845
pGBM 2735 30423 5149 16458 11587 8431
pGBM 2757 20331 3224 11469 5863 3850
pGBM 2854 16473 3507 31545 6160 4135
pGBM 2884 22520 3867 11169 3910 2412
pGBM 2896 18772 3692 21197 5594
pGBM 3007 35081 6034 25479 4176 7502 7393
pGBM 3031 422 567
pGBM 3032 23106 4075 21910 3737 5109 5755
pGBM 3066 7374 4665 966
pGBM 3070 11779 9861
pGBM 3513 15812 2648 13211 1889 3364 3997
pGBM 3747 3935 35837 4589 9197
GBM oligo 2655 5707 16105 3979
GBM RZ 3527 19454 3971 16649 3240 2610 2390
GBM sark 2643 15336 9016
GBM sark 3555 15783 1412 8804 4047 2729
Normal Brain NBfrontal 19221 2402 9947
Normal Brain NBoccipital 17043 2654 8193
Normal Brain NBparietal 27201 3259 15137
Normal Brain NBtemporal 9943 5267
AII 1418 10382 27422 3413 9416
pGBM LÜ 820 18678 17925
pGBMsark 176 13646 6486
sGBM 677 22717 4536 16365 6843 5106
sGBM 1214 14151 22018
sGBM 1329 25454 4341 13992 2448 3946 3066
sGBM 1430 8732 13920 2573
sGBM 1944 2784 1408
sGBM 2007 25122 13291 5809 4136
sGBM 2727 13130 13388 2144
sGBM 3475 9065 25518 4897 6035
GBM cells A172 31735 3767 4119 3787
GBM cells LN229 22869 5466 1544 2998
GBM cells LN428 32980 3384 8621
GBM cells T98G 43905 3575
GBM cells U178 48671
more abundant in normal brain tissue and reduced or lacking in tumors
more abundant in glioma tissue and reduced or lacking in normal brain tissues
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CPEB3d CPEB3c CPEB3b CPEB3a
Diagnose ID-T-Nummer CPEB3 100 bp 104 bp 122 bp 135 bp 143 bp 182 bp 203 bp 254 bp 452 bp 507 bp 531 bp 547 bp 576 bp 600 bp
AAIII 2377 14978 7471
AAIII 2526 16481 5174
AAIII 2725 8565 5827
AAIII 2744 1336 8779 3911
AAIII 2771 11567
AAIII 2897 10303 3297 7329 6800
AAIII 2899 9728 5401 1662
AAIII 3423 8332 7130 3319
AAIII 3545 10263 1937 6631 5312
AAIII 3546 10090 7658
AAIII 3548 2244 950 14927 5418 1641
AAIII 4045 2809 967 1267 6986
pGBM 71 975 2644
pGBM 72 890 12224 3767
pGBM 132 2960
pGBM 172 5473
pGBM 327 4332
pGBM 328 11773 3715
pGBM 625 3411 1331 9924 4181
pGBM 862 2902 4307
pGBM 1010 2482 3189 3926
pGBM 1311 1697 5664 4930
pGBM 1619 8481 2164
pGBM 1968 1309 12571 3929
pGBM 2010 1832 11890 4069 5785
pGBM 2104 1684 9475 5370
pGBM 2169 2010 2775 2038 1369 7456
pGBM 2304 3064 6016 5035
pGBM 2481 4655 1948
pGBM 2486 13216 5885
pGBM 2494 7194 4258
pGBM 2735 3702 19438 6404
pGBM 2757 7269 3233
pGBM 2854 2848 11950 4230
pGBM 2884 906 2270 3166
pGBM 2896 8291 3573
pGBM 3007 3215 1769 12083 2690 8418 4942
pGBM 3031 1302 1394 13680 2416 5531
pGBM 3032 1488 1435 11285 5442
pGBM 3066 937 5000
pGBM 3070 2843 2916
pGBM 3513 1274 958 7020 5493
pGBM 3747 1060 13025 5380
GBM oligo 2655 6427 5669
GBM RZ 3527 14338 8036
GBM sark 2643 1052 2988
GBM sark 3555 1790 7409 4267
Normal Brain NBfrontal 2786 3347 6109
Normal Brain NBoccipital 2747 1313 3014 4169
Normal Brain NBparietal 2224 4410 8886
Normal Brain NBtemporal 2423 4662
AII 1418 10694 3442
pGBM LÜ 820 781 14046 9726
pGBMsark 176 1821 994
sGBM 677 1794 16129 5345
sGBM 1214 10861 4527
sGBM 1329 5077 3081
sGBM 1430 2564 1991
sGBM 1944
sGBM 2007 1156 12615 5049
sGBM 2727 3751 2626
sGBM 3475 12062 4703
GBM cells A172 4055 4301 8985 4284
GBM cells LN229 2498 2219
GBM cells LN428 8673 5298
GBM cells T98G 1685 1524
GBM cells U178 9331 1442 10162 1469 9216 3498
more abundant in normal brain tissue and reduced or lacking in tumors
more abundant in glioma tissue and reduced or lacking in normal brain tissues
Detected splice isoforms:
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Detected splice isoforms: CPEB4d CPEB4c CPEB4b CPEB4a
Diagnose ID-T-Nummer CPEB4 115 bp 142 bp 182 bp 203 bp 226 bp 254 bp 277 bp 306 bp 507 bp 547 bp
AAIII 2377 21149 21655
AAIII 2526 19619 19174 1675
AAIII 2725 26046 20165
AAIII 2744 21718 25345
AAIII 2771 16637 12207 7133
AAIII 2897 26150 5221 22566 4984
AAIII 2899 19046 1503 15869 1628
AAIII 3423 9538 8597 1103
AAIII 3545 19463 25298
AAIII 3546 22665 20903
AAIII 3548 21383 22958 2407 2125
AAIII 4045 26882 32885 2864
pGBM 71 7320 4185
pGBM 72 15172 15587
pGBM 132 6518 5536
pGBM 172 17460 4028 9620 6182
pGBM 327 12086 8460
pGBM 328 25485 21644
pGBM 625 2634 30452 11702
pGBM 862 3500 15071 5445
pGBM 1010 22305 14188
pGBM 1311 22087 17696
pGBM 1619 14804 15511
pGBM 1968 33990 34922
pGBM 2010 22114 21939 10977
pGBM 2104 20095 12555 2397
pGBM 2169 49763 37272
pGBM 2304 16788 13189
pGBM 2481 14181 14563
pGBM 2486 1526 25177 22191 1216
pGBM 2494 13383 10394 2237
pGBM 2735 22615 30332 2482
pGBM 2757 13014 16528
pGBM 2854 1810 27502 17757
pGBM 2884 9538 11158
pGBM 2896 21392 15304 2357
pGBM 3007 40036 32132
pGBM 3031 35312 23592
pGBM 3032 37298 26434
pGBM 3066 8825 7801
pGBM 3070 9167 6748
pGBM 3513 21270 2580 19710 3011
pGBM 3747 21631 25574
GBM oligo 2655 11793 9233 2176
GBM RZ 3527 22106 22278
GBM sark 2643 18032 12070
GBM sark 3555 4261 11334 9271 5636
Normal Brain NBfrontal 9860 6940 6026 6231
Normal Brain NBoccipital 8343 8381 5602 7068
Normal Brain NBparietal 20994 14305 11481 10482
Normal Brain NBtemporal 9343 7008 5371 5927
AII 1418 19617 20652
pGBM LÜ 820 20257 13442 1764
pGBMsark 176 9898 5532
sGBM 677 17046 17065 1621
sGBM 1214 16456 2722 14162 2717
sGBM 1329 6742 4778
sGBM 1430 15947 2555 9824 2453
sGBM 1944 8971 3747
sGBM 2007 18669 15918
sGBM 2727 17089 10782
sGBM 3475 11656 16539
GBM cells A172 20800 12084
GBM cells LN229 14344 10688
GBM cells LN428 15692 12416
GBM cells T98G 27548 7879
GBM cells U178 38061 17132
more abundant in normal brain tissue and reduced or lacking in tumors
more abundant in glioma tissue and reduced or lacking in normal brain tissues
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5.2 Alterations of growth properties and cancer-associated parameters in 
glioblastoma-derived cells mediated by CPEBs 
5.2.1 Expression profile of CPEB 1-4 in A172 cultured glioblastoma cells 
Altered expression of CPEBs in high- and low-grade gliomas indicated their role in the 
translational regulation in cancer. CPEB protein activity was studied in human glioma 
specimens and described in the previous section (see chapter 5.1.3.1). The current 
investigation addressed a potential influence of CPEBs on glioblastoma cells in vitro. With 
this intention, endogenous CPEB expression was monitored in human A172 glioblastoma 
culture (Fig. 5.2.1-1). Among CPEB paralogs, the most prominent expression was observed 
in CPEB 2-4. Proteins were detected as a punctate staining in the cytoplasm of investigated 
cells. Expression of CPEB1 and phospho-CPEB3 appeared to be reduced. Although all 
CPEBs are able shuttle to the nucleus (Kan et al., 2010), here, only phospho-CPEB3 and 
CPEB3 were observed in cell nuclei.  
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Figure 5.2.1-1. Endogenous expression of CPEB1-4 and phospho-CPEB3 proteins in human A172 
glioblastoma culture cells. Starting from the left, the panels show staining of individual CPEBs, DAPI and 
their merged staining. Scale bars represent 25 μm. 
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5.2.2 Functional characterization of CPEB1 and CPEB2 protein overexpression 
in cultured A172 glioblastoma cells 
5.2.2.1 Overexpression of CPEB1 and CPEB2 proteins  
The contribution of CPEBs to the molecular pathogenesis of glioblastoma was investigated 
by overexpression of CPEB1 (n=4) and CPEB2 (n=7) proteins in glioblastoma-derived 
cells (Fig. 5.2.2.1-1). Next, A172 cultures transiently overexpressing CPEB1 or CPEB2 
protein were investigated with regard to proliferation, apoptotic activity and migration. 
 
 
Figure 5.2.2.1-1. Overexpression of CPEB1 and CPEB2 proteins in A172 glioblastoma culture. A, C: 
Representative immunoblot showing overexpression of CPEB1, CPEB2 proteins and tubulin as an internal 
control. B, D: Analysis of the immunoblots of CPEB1-pCMV/Neo (n=4) and CPEB2-pCMV/Neo (n=7) 
transfected cells in comparison to reference pCMV6/Neo vector. 
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5.2.2.2 Alteration of proliferation and apoptotic activity of glioblastoma cells 
mediated by CPEB1 and CPEB2 proteins 
The influence of CPEB overexpression on proliferation and apoptosis of cultured A172 
cells was identified by flow cytometric analysis. In each experiment 100000 GFP-CPEB1-
pCMV6/Neo, GFP-CPEB2-pCMV6/Neo or control GFP-pCMV6/Neo transfected cells 
were analyzed. Apoptotic, cPARP+ cells were labeled by antibodies against poly(ADP-
ribose) polymerase (Asp214), while proliferating, pHH3+ cells were detected by antibodies 
against Ser10-phosphorylated histone H3. Overexpression of CPEB1 resulted in 1.75-fold 
growth of the apoptotic cellular population. In contrast, overexpression of CPEB2 resulted 
in a decrease in apoptosis (to 70%). Proliferation appeared to be not affected by CPEB 
overexpression (Fig. 5.2.2.2-1). 
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Figure 5.2.2.2-1. Flow cytometric analyses performed in A172 glioblastoma cells overexpressing CPEB1 
or CPEB2 protein. Proliferating cells (pHH3+) were detected by antibodies against Ser10-phosphorylated 
histone H3, whereas apoptotic cells (cPARP+) by antibodies against poly(ADP-ribose) polymerase (Asp214). 
In each experiment at least 100000 GFP- CPEB1-pCMV6/Neo, GFP- CPEB2-pCMV6/Neo, GFP- 
pCMV6/Neo or GFP positive cells were analyzed. Cells transfected with GFP- pCMV6/Neo or GFP vector 
were considered as reference. Non-transfected cells labeled with pHH3 or stimulated with 1 μM staurosporine 
and stained with PARP antibody were considered as a proliferation and apoptosis control. 
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5.2.2.3 Influence of CPEB1 and CPEB2 overexpression on glioblastoma cells 
migration  
 
The impact of CPEBs on cell migration was determined by overexpression of CPEB1 or 
CPEB2 protein in cultured glioblastoma cells followed by an in vitro scratch assay (Fig. 
5.2.2.3-1A). Since FACS analysis (see Fig. 5.2.2.2-1) did not reveal any effect of increased 
CPEB expression on proliferation, the presence of cells in the wounded area was associated 
with their enhanced migratory capability. The change in the area covered by migrating cells 
over the time was raised up to 30% and 20% by elevated CPEB1 and CPEB2 protein levels, 
respectively (Fig. 5.2.2.3-1B). 
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Figure 5.2.2.3-1. Influence of CPEB1 and CPEB2 overexpression on migration of cultured A172 
glioblastoma cells A: Motility of CPEB1 and CPEB2 overexpressing cells examined by an in vitro wound 
healing assay. Scale bars represent 100 μm. B: Quantification of the change in the cell-covered area over time 
(24h) upon elevated expression of CPEB1 (n=4) and CPEB2 (n=4) proteins. Error bars indicate standard error 
of the mean. 
 
5.2.3 Identification of cancer-associated signaling pathways altered by CPEB1 
and CPEB2 proteins 
Changes in cancer-associated signaling pathways induced by CPEBs were investigated by a 
cell-based pathway reporter array. Quantitative evaluation was possible upon 
overexpression of CPEB1 and CPEB2 in cultured cells and its reverse transfection with 
reporters of transcription factors present at the array plate. Increased expression of CPEB1 
revealed a significant upregulation of estrogen, hedgehog, HNF4 and TGFβ pathways (Fig. 
5.2.3-1A). In contrast, elevated expression of CPEB2 protein resulted in upregulation of c-
myc, oct4, PI3K/Akt and TGFβ cascades (Fig. 5.2.3-1B). Since overexpression of CPEB1 
proteins led to enhancement of TGFβ activity, it might indicate that the detected cascade is 
a novel target for translational regulation by CPEBs 
Results 
 
112 
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Figure 5.2.3-1. Cancer-associated signaling pathways altered by CPEB1 and CPEB2 proteins. A: 
Changes in cancer-associated signaling pathways monitored by cell-based reporter assays (n=3) revealed a 
significant upregulation of estrogen, hedgehog, HNF4 and TGFβ upon CPEB1 overexpression. Error bars 
indicate SEM. B: Upregulation of myc, oct4, PI3K/Akt and TGFβ signaling pathways upon CPEB2 
overexpression (n=2; statistical quantification was not performed). 
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5.3 Expression profile of CPEB2 protein in mouse brain 
5.3.1 Expression of CPEB1 and CPEB2 proteins in primary hippocampal 
cultures 
In neurons, proteins involved in synaptic plasticity are predominantly derived from RNA 
molecules localized in dendrites. In response to synaptic stimulation, CPE elements present 
in the 3’UTR of dendritic mRNAs and CPE binding proteins promote translation induced 
by cytoplasmic polyadenylation. CPEBs also facilitate transport of mRNAs to dendrites. 
Localization of CPEB1 in cultured neurons has been observed in both, dendrites and cell 
bodies (Huang et al., 2003). Here, the expression of CPEB1 and CPEB2 was examined in 
rat primary hippocampal cultures. Neurons were co-stained with antibodies against CPEB1, 
CPEB2 and neuronal marker MAP2. Subcellular localization of both CPEBs overlapped in 
cultured neurons. Punctate distribution of expressed CPEB2 was observed in dendrites and 
the soma, similar to CPEB1 (Fig. 5.3.1-1). 
 
 
Figure 5.3.1-1. Endogenous expression of CPEB1 and CPEB2 in primary hippocampal neurons. 7 days 
in vitro hippocampal cultures prepared from Wistar rats were stained with CPEB1 (green), CPEB2 (green), 
MAP2 (red) antibodies and Hoechst counterstain (blue). Scale bars represent 25 μm. 
Results 
 
115 
 
5.3.2 Expression of CPEB2 protein in juvenile and adult mouse brain 
Expression pattern of CPEB2 protein in juvenile (p12) and adult (p90) C57Bl6J mouse 
brain was determined with custom made CPEB2 antibody directed to mouse and human. 
Antibodies specifically recognized CPEB2a and CPEB2a* splice variants containing the B- 
and C-region and did not cross-react with other CPEBs (Turimella et al., 2015). Expression 
of CPEB2 was explored in neurons of different brain areas by immunostaining. Coronal 
sections from corresponding age groups were stained with antibodies against CPEB2 and 
the neuronal marker MAP2. The vast majority of MAP2 positive neurons in the CA1 region 
of the hippocampus, striatum radiatum, thalamus, cortex, and cerebellum displayed 
immunoreactivity against CPEB2 (Fig. 5.3.2-1). In individual cells of juvenile and adult 
animals, CPEB2 was located in the cytoplasm and processes. Dendritic localization of 
CPEB2 seemed to be more prominent in adult animals (Fig. 5.3.2-1B). 
Results 
 
116 
 
 
Results 
 
117 
 
 
Figure 5.3.2-1. 
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Figure 5.3.2-1. Examination of CPEB2a and CPEB2a* expression in (A) juvenile (p12) and (B) adult 
(p90) C57Bl6J mice brains. Representative confocal images of CPEB2 (green), MAP2 (red), and Hoechst 
(blue) staining in the hippocampal CA1 region, striatum radiatum (STR), thalamus (TH), cortex (CTX), and 
cerebellum (CB). Scale bars represent 50 μm. 
 
5.3.3 Differential expression of CPEB2 in excitatory, inhibitory and dopaminergic 
neurons 
Differential expression of CPEB2 in excitatory, inhibitory, and dopaminergic neurons was 
assessed by immunostaining. 42.26±15.9% (n=3) of the GFP positive excitatory neurons in 
the hippocampus and dentate gyrus demonstrated CPEB2 immunoreactivity in Thy1-GFP 
mice (Fig. 5.3.3-1.). Further, in wild-type C57Bl6J mice, 93.6±9% (n=3) of the 
hippocampal inhibitory neurons and 62.36±9% (n=3) of the midbrain dopaminergic 
neurons demonstrated CPEB2 immunoreactivity (Fig. 5.3.3-1.). CPEB2 protein occurred to 
be heterogeneously expressed among investigated types of neurons and its strongest 
expression was observed in parvalbumin positive inhibitory neurons. 
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Figure 5.3.3-1. Endogenous expression of CPEB2 in excitatory, inhibitory, and dopaminergic neurons. 
Staining of GFP (green) and CPEB2 (red) or parvalbumin (PARV; red), tyrosine hydroxylase (TYH; red), and 
CPEB2 (green) was combined with Hoechst counterstain (blue). Scale bars represent 50 μm. 
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6 DISCUSSION 
 
Understanding the molecular pathophysiology of tumors is fundamental to identify novel 
therapeutic and diagnostic factors. Thus far, cancer-related genes were abundantly 
investigated by transcript-based microarrays (van den Boom et al., 2003; Phillips et al., 
2006; Rickman et al., 2001). In addition to these analyses, a recent study emphasizes the 
importance of post-transcriptional modification regulating gene expression changes under 
physiological conditions, but also giving rise to the pathology of tumors (Ortiz-Zapater et 
al., 2012). Translational control is particularly relevant in aggressive and therapy resistant 
malignancies. Despite reports endorsing the role of CPEBs in polyadenylation-induced 
translation in gliomas (Hu et al., 2015; Kochanek and Wells, 2013; Ortiz-Zapater et al., 
2012), our knowledge of CPEB properties and their physiological relevance is incomplete. 
Thus far, the main research effort was focused on characterization of CPEB1. However, 
other members of the CPEB family mediate equally important processes, including synaptic 
plasticity and cancer formation (Ivshina et al., 2014). Furthermore, regardless of structural 
similarities, CPEBs are functionally non redundant (Ivshina et al., 2014). Therefore we 
chose to carefully examine the functional aspects of the CPEB isoforms in the developing 
and diseased brain. 
 
6.1 The role of CPEBs in development and progression of glioma 
6.1.1 Expression of CPEBs is heterogeneous in human glioma tissues 
To examine functions of each of the CPEB subtypes in human glioma tissue, the present 
study focused on the expression patterns by comparing glioma tissues of different WHO 
grades. For this purpose, the abundance and localization of CPEBs was determined by 
immunohistochemistry. The vast majority of CPEB1 expression was detected in the 
infiltration areas of tumor cells into normal brain tissue. Cells in the tumor center, in the 
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areas of necrosis and angiogenesis, lacked CPEB1 (Fig. 5.1.3.1-1). It is generally known 
that tumor cells may adapt to the local environment or change the surrounding towards their 
own benefit (Godlewski et al., 2014). The fact that CPEB1 expression was reduced in 
GBMs may suggest a proto-oncogenic adaptation. Interestingly, expression of CPEB1 was 
downregulated with WHO grade, reaching the lowest level in GBMs (Fig. 5.1.3.1-2A; Tab. 
5.1.3.1-1). A similar expression course was shown in the recent study of Galardi et al. 
(2016), where CPEB1 mRNA level was maximum in normal brain and significantly 
reduced in cancer tissues. In line with these findings, CPEB1 was indicated to be a putative 
tumor suppressor (D’Ambrogio et al., 2013). Abundant evidence form ovarian, melanoma, 
and gastric cancers and cell lines derived from breast, myeloma and colorectal cancer 
(Caldeira et al., 2012; Hansen et al., 2009; Heller et al., 2008; Nairismägi et al., 2012; 
Shoshan et al., 1999) report reduction in CPEB1 transcript and suggest a potential tumor 
repressing role. Furthermore, downregulation of CPEB1 in tumor cells disturbs the mitotic 
regulation of poly(A) tails, pre-mRNA alternative polyadenylation site selection, and 
inhibits cell proliferation (Bava et al., 2013; Giangarrà et al., 2015b; Novoa et al., 2010). In 
contrast, reduction of CPEB1 in primary fibroblasts is associated with bypass of senescence 
(Burns and Richter, 2008; Fernández-Miranda and Méndez, 2012) and the ability of tumor 
cells to enhance invasion, angiogenesis and to increase resistance to nutritional stress 
(Grudzien-Nogalska et al., 2014). Also knockout of CPEB1 induces epithelial-to-
mesenchymal transition (Grudzien-Nogalska et al., 2014), a process that is associated with 
increased cancer progression and metastatic potential (Kalluri and Weinberg, 2009). From 
these results it can be concluded that expression of CPEB1 is reduced in various cancers in 
order to support tumor development and progression.  
To a certain extent, the expression pattern of CPEB2 was similar to CPEB1. Prevalent 
CPEB2 immunoreactivity was observed in less aggressive AII and AAIII, while pGBM 
specimens were negative or showed very weak CPEB2 staining (Fig. 5.1.3.1-2B; Tab. 
5.1.3.1-1). CPEB2 was found in reactive astrocytes and in endothelial tumors cells, 
suggesting that protein synthesis takes place in the close proximity of blood vessels during 
tumor formation (Fig. 5.1.3.1-1). One of the possible explanations for CPEB2 expression in 
endothelial cells may be association of CPEB2 with stress conditions. It was shown that 
increased oxidative stress provokes CPEB2 binding to HIF-1α mRNA and regulates its 
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expression (Hägele et al., 2009). In turn, HIF-1α controls homeostatic responses to 
oxidative stress by stimulating transcription of genes involved in angiogenesis, metabolism 
and cell survival (Chen et al., 2015). However, further research is needed to explain the role 
of CPEB2 in hypoxia and vascularization. 
In the investigated cohort of gliomas, CPEB3 was the most abundantly expressed family 
member (Fig. 5.1.3.1-1). The present study provides the first analysis of CPEB3 in human 
glioma specimens. In contrast to CPEB1 and CPEB2, its immunoreactivity increased with 
progressing tumor grade, and achieved the strongest intensity in GBMs (Fig. 5.1.3.1-2C; 
Tab. 5.1.3.1-1). At the same time, the activity of the protein, determined by its 
phosphorylation, decreased with WHO grade (Fig. 5.1.3.1-2D; Tab. 5.1.3.1-1). Therefore, 
despite the strong CPEB3 expression, phospho-CPEB3 in GBMs was distinctly reduced. 
This suggests that a substantial part of CPEB3 protein in GBM specimens does not undergo 
phosphorylation and indicates phosphorylation to be the biologically significant mechanism 
regulating CPEB3 activity in gliomas. 
In contrast to the other CPEBs, strong expression of CPEB4 was solely observed in a few 
of the investigated glioma specimens (Fig. 5.1.3.1-2E; Tab. 5.1.3.1-1), with a prominent 
immunoreactivity in cell processes (Fig. 5.1.3.1-1). This localization of CPEB4 indicates its 
involvement in local protein synthesis, which was shown to be particularly important for 
synaptic plasticity (Kandel, 2001; Zukin et al., 2009), but may also contribute to 
cancerogenesis. CPEB4 may be implicated in the syntheses of proteins involved in cell-cell 
communication and tumor-stromal interactions (Ortiz-Zapater et al., 2012), thus indirectly 
in cancer progression. Indeed, downregulation of CPEB4 was associated with tumor 
development (Giangarrà et al., 2015). Cells overexpressing CPEB4 showed an advantage 
for tissue colonization and invasion (Fernández-Miranda and Méndez, 2012), while its 
downregulation resulted in reduction of cellular proliferation in the GBMs and PDAs 
(Ortiz-Zapater et al., 2012). Knockdown of CPEB4 contributed to a decrease of tumor size 
and vascularization, indicating its impact on changes in cell proliferation (Ortiz-Zapater et 
al., 2012). In the present study the expression pattern of CPEB4 could not be associated 
with the WHO grade. However Hu et al. (2015) reported CPEB4 to enhance tumor 
progression in human high-grade gliomas. Considering that high CPEB4 expression 
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supports tumorigenic properties, this isoform might be involved in local protein synthesis 
and mediate cancer progression. 
Altogether, these observations are in agreement with the fact that CPEB expression is 
heterogeneous in human gliomas. Destabilization of the normal function of a wide range of 
transcripts regulated by CPEB favors tumor growth. Therefore, CPEB-dependent 
translational control may be considered as a mechanism having a significant role during 
glioma formation and progression. 
 
6.1.2 CPEB expression patterns associate with clinical prognosis of glioma 
patients 
Since in the present study a decrease in CPEB1 and phoshop-CPEB3 was observed with 
increasing tumor grade, the potential prognostic value of CPEB expression in human 
glioma specimens was assessed by Kaplan-Meier survival analysis. CPEB expression 
profiles compared with the clinical data revealed an interesting dependency between 
CPEB1, phospho-CPEB3 and life expectancy. A pronounced association of CPEB1 
expression with prolonged survival was observed in AII and AAIII, but not in GBM 
specimens (Fig. 5.1.3.2-1A, B). Though it is necessary to keep in mind that low-grade 
astrocytoma patients usually progress better, recent reports support a link between reduced 
CPEB1 expression and longer survival (Galardi et al., 2016; Yin et al., 2014). Despite the 
robust expression of CPEB 2-4, none of the proteins showed correlation with patient 
survival (Fig. 5.1.3.2-1C, D, G). However, Hu et al. (2015) reported that a high CPEB4 
expression profile was associated with shorter survival of GBM patients. Interestingly, 
there was a difference in the survival of patients with and without phospho-CPEB3. A 
significant correlation between CPEB3 activity and survival was observed in less 
aggressive low-grade astrocytomas considered to be sGBM precursors (Fig. 5.1.3.2-1E), 
but not in pGBMs (Fig. 5.1.3.2-1F). In order to ascertain an association between survival 
and phospho-CPEB3 expression in GBMs, an increased number of specimens should be 
retested. In general, the data presented here support the hypothesis that CPEBs may serve 
as a sensitive prognostic factor for glioma patients.  
Discussion 
 
124 
 
6.1.3 Methylation of CPEB1 gene does not correlate with silenced expression 
Hypermethylation of DNA is a frequent condition in cancers (Chen et al., 2014), resulting 
in stable transcriptional silencing of the associated genes (Jones and Baylin, 2007). This is 
due to the methyl groups that attach to the CpG islands localized in the promoter region, 
which impede the binding of transcription factors (Chen et al., 2014). The finding that 
CPEB1 expression was gradually decreasing with tumor progression, suggested increased 
DNA methylation (Curradi et al., 2002). To test this hypothesis genome wide DNA 
methylation analysis was performed. Methylation of CPEB genes was formerly studied in 
tumors (Caldeira et al., 2012; Heller et al., 2008), but hypermethylation in gliomas was 
never reported. Among the investigated genes, CPEB1 and CPEB3 were methylated (Fig. 
5.1.1-1), however only CPEB1 reached prominent hypermethylation level. CPEB1 
methylation was additionally associated with mutation in the IDH gene (Fig. 5.1.2-1). 
Recent studies proved that IDH mutations, not only drive an increased promoter 
methylation, but actually entail hypermethylation (Christensen et al., 2011; Labussiere et 
al., 2010), and associate with improved prognosis of glioma patients (Cohen et al., 2013).  
In the present study a significant reduction in CPEB1 expression on a transcript level was 
detected in AAIII and sGBM specimens containing increased methylation and IDH1 
mutation (Fig. 5.1.1-1). Although this observed trend was indicating a link between the 
high CPEB1 methylation and silenced expression it turned out not to be correlated. 
Therefore, the observed DNA methylation only partially may be involved in transcriptional 
repression of CPEB1. Interestingly, pGBM specimens, with wild type IDH1, where CPEB1 
methylation was not detected also revealed reduced expression of CPEB1 transcript (Fig. 
5.1.1-1). This allows concluding that CPEB1 expression in pGBM samples was reduced 
independently of the methylation status. Consequently, other epigenetic and non-epigenetic 
mechanisms play a role in transcription silencing. For instance microRNAs may contribute 
to blocking translation or promoting degradation of the transcripts (Burns et al., 2011; 
Morgan et al., 2010), and explain the reduction of CPEB1 expression. Although in the 
present study DNA methylation turned out not to be responsible for CPEB1 
downregulation, promising results from clinical trials with DNA methylation inhibitors as 
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well as histone deacetylase inhibitors were recently reported, meaning that epigenetic 
approaches have a potential in cancer therapy (Chen et al., 2014).  
 
6.1.4 Expression of CPEB3 and active CPEB3 protein is tissue specific  
The difference between expression levels of CPEB3 and phosphorylated CPEB3 gives a 
solid foundation to further examine kinases regulating CPEB function (Fig. 5.1.5-2). PKA 
and CaMKII investigated here are known to activate CPEBs phosphorylation that further 
triggers polyadenylation-induced translation (Kaczmarczyk et al., 2016; Theis et al., 2003). 
A recent study demonstrated that phosphorylation of CPEB3 depends on the presence of 
the alternatively spliced B-region, and can be detected by phospho-specific CPEB3 
antibody (Kaczmarczyk et al., 2016). The used antibody allowed for recognition of only 
one splice form of the protein containing a phosphorylation consensus sequence, namely 
the B-region adjacent to two serine (S419, S420) residues. The specificity of the phospho-
CPEB3 antibody was confirmed in cultured cells transfected with full-length CPEB3a 
(containing the B-region), CPEB3aKD (S419, S420 mutated to A419, A420), and CPEB3b 
(lacking the B-region) (Fig. 5.1.5-1), where only full-length CPEB3a was subject for 
phosphorylation.  
Since the alternatively spliced B-region and the overlapping phosphorylation site are 
conserved between CPEB 2-4, this site is strongly engaged in regulatory functions of 
CPEBs (Kaczmarczyk et al., 2016). The AII specimens analyzed here were characterized 
by robust expression of CPEB3 and phospho-CPEB3 (Fig. 5.1.5-2, right column), while 
pGBM specimens showed strong immunoreactivity against CPEB3 (Fig. 5.1.5-2, left 
column). Altogether, CPEB3, PKA and CaMKII kinases were abundantly expressed in both 
of the investigated groups, while phospho-CPEB3 protein was only present in AII (Fig. 
5.1.5-2). Despite the abundant CPEB3 expression and strong activity of kinases initiating 
polyadenylation, no significant phosphorylation of CPEB3 was observed in GBMs. This 
strongly suggests the lack of functional regions in the expressed CPEB3 and blockade of 
presumed targets expression. 
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6.1.5 Alternative splicing determines the expression pattern and activity of 
CPEBs 
As expression analysis of PKA and CaMKII kinases revealed no change in their 
immunoreactivity between low- and high-grade gliomas the next step was directed towards 
the investigation of alternative splicing of CPEBs. In eukaryotes, alternative splicing 
determines tissue differentiation, controls transcriptional and post- transcriptional 
mechanisms, and their role in cancer (Kornblihtt et al., 2013). Alternative splicing of 
CPEBs is particularly relevant in the context of cytoplasmic polyadenylation, because the 
splice variants of CPEB 2-4 differ in their regulation by phosphorylation due to presence or 
lack of respective consensus sites (Fig. 1.4.3-1; Fig. 5.1.6-1) (Kaczmarczyk et al., 2016; 
Theis et al., 2003). 
CPEBs are involved in the regulation of synaptic plasticity, and multiple splice variants of 
CPEB paralogs were observed in a mouse brain (Kaczmarczyk et al., 2016; Theis et al., 
2003; Turimella et al., 2015). In hippocampal pyramidal neurons, only CPEB2 splice 
variants containing the B-region, such as CPEB2 a/c were expressed. Two of the detected 
isoforms, CPEB2 a*/c*, contained an additional 9-nt E-region (Turimella et al., 2015). 
Furthermore, changes in the abundance of CPEB3 splice variants were induced by neuronal 
stimulation. As in the case of CPEB2, increased neuronal activity led to expression of 
CPEB3 isoforms containing the B-region (Kaczmarczyk et al., 2016). In cancers, 
alternative splicing of CPEB2 turned out to be a key driving mechanism in human TNBC 
metastasis (Johnson et al., 2015). The high metastatic potential of TNBC cells was 
associated with acquiring of anoikis resistance (AnR) and increase in expression of the B-
region-lacking isoform. Downregulation of the CPEB2b re-sensitized AnR cells to 
detachment and induced cell death, whereas overexpression of CPEB2b in TNBC cells 
generated the AnR and increased their metastatic potential (Johnson et al., 2015). In human 
glioma specimens, profiling of alternative splice variants revealed that in comparison to 
normal brain and low-grade astrocytomas, most of the GBMs lacked the full-length CPEBs 
(CPEB2a, CPEB3a, CPEB4a) (Fig. 5.1.6-2; Tab. 5.1.6-1B, C, D). Furthermore, the 
majority of GBM samples did not express the CPEB4c variant also containing the B-region 
(Tab. 5.1.6-1D). Instead, isoforms lacking the B-region (CPEB3b, CPEB3d, CPEB4b, 
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CPEB4d) were predominantly expressed (Fig. 5.1.6-2; Tab. 5.1.6-1C, D). Interestingly, the 
recently identified E-region was detected in CPEB2 c*/d* splice variants, but so far its 
function has not been addressed. Generally this observation indicated the loss of CPEB 2-4 
activity in high-grade gliomas. Alternative splicing appeared to be cell type-specific and 
depended on the grade of tumor malignancy. 
Summarizing, in physiological conditions, the B-region-containing splice variants are 
abundantly expressed (Kaczmarczyk et al., 2016; Turimella et al., 2015). In contrast, TNBC 
(Johnson et al., 2015) and GBM tumors show enforced expression of isoforms lacking the 
B-region. However, it is unknown whether similarly to breast cancers, splicing in GMBs is 
related to their metastasis potential. Certainly, binding of CPEB 2-4 to the target transcripts 
without the possibility to further activate their translation, might cause their translational-
arrest and in consequence silence mRNAs expression. Importantly, a similar pattern was 
observed for CPEB1. Mutant CPEB1 protein lacking regions of phosphorylation could not 
be activated, therefore kept the bound mRNAs in translational arrest (Kochanek and Wells, 
2013). Thus far, the question how alternative splicing of CPEBs in gliomas is regulated 
remains open. The finding that CPEB3 in GBMs is expressed as a form that cannot undergo 
activation suggests its contribution to changes in protein expression of high-grade gliomas. 
Therefore, CPEB3 may be considered as an attractive therapeutic target. 
 
6.2 The impact of CPEBs on growth properties and cancer-relevant parameters in 
cultured glioblastoma cells 
6.2.1 CPEB3 protein shuttle between nucleus and cytoplasm 
The reduction of CPEB1 expression observed in human GBM specimens prompted us to 
determine whether reversing this process results in acquisition of tumor suppressor 
properties by GBM cells. Likewise, overexpression of CPEB2 aimed to prove whether 
enhanced protein levels impact growth properties and cancer-relevant parameters. 
Therefore, the A172 GBM line was selected as it expressed CPEB1 and CPEB2 (Fig. 5.2.1-
1) similar to human glioma specimens (Fig. 5.1.3.1-1).  
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Similarly to the investigated glioma tissues, endogenous CPEB levels in the cell line were 
heterogeneous. Weak cytoplasmic expression of CPEB1 was contrasted with abundantly 
expressed CPEB 2-4 (Fig. 5.2.1-1). Intriguingly, phospho-CPEB3 and partially CPEB3 
were observed in the cell nuclei (Fig. 5.2.1-1). However, as this was not the case in the 
investigated human gliomas the observed pattern was assumed as a culture artefact. 
 
6.2.2 Forced overexpression of CPEB1 and CPEB2 alters growth properties and 
cancer-associated parameters of glioblastoma cells 
CPEBs regulate important cellular processes such as astrocyte migration (Jones et al., 
2008), or MEF growth and senescence (Fernández-Miranda and Méndez, 2012). Recently 
CPEBs were found to be expressed in gliomas (Galardi et al., 2016; Ortiz-Zapater et al., 
2012). Therefore it is important to identify whether their altered expression evoke changes 
in growth properties or cancer-associated parameters of GBM cells. The high levels of 
CPEB1 turned out to be cytotoxic for cultured GBMs. Overexpression of CPEB1 resulted 
in meagre growth of apoptotic cell population. In contrast, overexpression of CPEB2 
slightly decreased apoptotic activity of GBM cells, suggesting that higher CPEB2 level 
may possibly result in loss of its tumorigenic properties. Alterations in cellular proliferation 
of CPEB1 and CPEB2 were not observed (Fig. 5.2.2.2-1). Overexpression of CPEB1 was 
recently reported to reduce proliferation and infiltration of GBM cells (Galardi et al., 2016; 
Yin et al., 2014). Accordingly, CPEB1 was directly engaged in regulation of p27
Kip1
 
expression (Galardi et al., 2016). However, despite CPEB1 reduction, Nagaoka et al., 
(2016) found no effect on cell proliferation in the investigated mouse mammary epithelial 
cells. Likewise, knockout of CPEB1 in MEFs resulted in no difference in cell cycle 
progression. Instead, MEFs as well as primary human cells escaped senescence. This 
process was shown to be mediated by reduced expression of CPEB1-dependent mRNAs, 
such p53 and c-myc (Burns and Richter, 2008; Groisman et al., 2006). 
Enhanced migration of transformed astrocytes leads to spread of tumors and a high 
recurrence rate (Stupp et al., 2005). This process not only involves changes in the 
cytoskeleton, but also depends on the synthesis of new proteins (Jones et al., 2008). New 
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protein synthesis was shown to be especially important in the migration of astrocytes into a 
site of the injury, and the process was precisely regulated by CPEB1-mediated synthesis of 
β-catenin in the leading edge of invading cells (Jones et al., 2008). In the present study, 
forced overexpression of CPEB1 and CPEB2 also enhanced the cell motility (Fig. 5.2.2.3-
1). Therefore, it is highly possible that migration of cultured GBM cells is regulated by 
CPEB-dependent synthesis of β-catenin. Additionally, based on findings from FACS 
analysis, the wound healing was speeded up rather by elevated cell motility than by 
increased proliferation.  
One of the possible explanations for enhanced apoptotic activity and migration by CPEB1 
might be that the faster migration generates rapid changes in cytoskeleton. These 
morphological alterations on one hand may contribute to increased cell motility, but may 
also raise a chance of mistakes turning GBM cells towards an apoptotic pathway. In 
contrast, decreased apoptotic activity and enhanced migration through CPEB2 may indicate 
that CPEB2 overexpressing cells are losing their cancerous properties. 
 
6.2.3 Elevated expression of CPEB1 upregulates cancer-associated signaling 
pathways 
Altered expression of CPEBs in human glioma specimens may entail changes in associated 
signaling pathways. Therefore, cultured GBM cells overexpressing CPEBs were seeded on 
multi-pathway assay plates that allowed for identification of CPEB-mediated changes in 
cancer-relevant cascades. Overexpression of CPEB1 enhanced the activity of estrogen, 
hedgehog, HNF4 and TGFβ (Fig. 5.2.3-1A). Overexpression of CPEB2 could not be 
quantitatively asset because the experiments number was too low (Fig. 5.2.3-1B). Among 
the upregulated pathways, TGFβ appeared to be the most prominent. Depending on the 
cellular context, TGFβ may result in tumor-suppressing or tumor-promoting activity 
(Derynck et al., 2001; Siegel and Massagué, 2003). In order to bypass a cell cycle 
inhibition, a majority of the cancers accumulate mutations in this pathway. TGFβ restrains 
proliferation of astrocytes, epithelial, and immune cells. However, in gliomas TGFβ may 
act as an oncogenic factor due to enhancement of cell proliferation, invasion, angiogenesis 
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and inhibition of immune response (Massagué, 2008; Seoane, 2006; Wesolowska et al., 
2008; Zhang et al., 2012).  
An association between CPEB1 and TGFβ pathway was independently confirmed by 
Nagaoka et al. (2016). They found that mouse mammary epithelial cells deprived of 
CPEB1 and treated with TGFβ show enhanced epithelial-to-mesenchymal transition and 
metastatic potential. Thus far, the mechanism triggering CPEB1-mediated TGFβ activation 
is unclear. However, TGFβ downstream targets, including Smad 2-4 were abundantly 
studied in gliomas (Bruna et al., 2007). High TGFβ-Smad activity was predominantly 
present in aggressive gliomas and related to the poor patient prognosis (Bruna et al., 2007). 
Therefore, inhibitors of the TGFβ pathway results in anti-tumor properties, such as 
reduction of cell viability and invasion (Kaminska et al., 2013). Inhibitor of the TGFβ 
receptor I kinase (galunisertib, LY2157299) that downregulates the phosphorylation of 
Smad2 and selectively block TGFβ pathway is currently investigated with a temozolomide-
based radio-chemotherapy in newly diagnosed GBM patients. Summing up, CPEBs are 
involved in regulation of the TGFβ signaling cascade. However, further studies are needed 
to fully explain the interaction between CPEB1-mediated translational control and the 
activation of the TGFβ pathway. 
 
6.3 Expression of CPEB2 in different cellular populations, brain regions, and stages 
of development 
 
Expression of CPEB1 was well described in the hippocampal neurons (Theis et al., 2003), 
therefore it served as a reference for the present study of CPEB2. Both CPEB paralogs 
demonstrated analogous subcellular localization and immunoreactivity in primary 
hippocampal neurons (Fig. 5.3.1-1). Expression of CPEB2 was present in most of the 
neurons throughout the investigated mouse brain regions (Fig. 5.3.2-1), including majority 
of excitatory, inhibitory and dopaminergic cells (Fig. 5.3.3-1). This indicated a role of 
CPEB2 in physiology of the juvenile and adult brain. In addition, localization of CPEB2 in 
cell bodies and dendrites, pointed at its role in control of local protein synthesis. This raised 
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the question of which neuronal mRNAs are regulated by CPEB2. Indeed, CPEB2 may 
regulate CaMKII, the kinase engaged in LTP (Atkins et al., 2005) and β-catenin, which is 
involved in neuronal morphogenesis (Yu and Malenka, 2003). Additionally, Turimella et 
al. (2015) identified EphA4 as a novel CPEB2 target. EphA4 not only participates in the 
neuron–glia crosstalk (Carmona et al., 2009), but also controls LTP at excitatory synapses 
(Filosa et al., 2009). Overall, this indicates involvement of CPEB2 in synaptic plasticity 
and local protein synthesis in the hippocampal neurons of developing and adult brain. 
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7 SUMMARY 
 
Gliomas are the most common primary brain tumors with aggressive progression and 
devastating prognosis. Therefore identification of new therapeutic and diagnostic factors is 
necessary to improve the dramatic situation of glioma patients. Thus far, cancer-related 
genes were thoroughly analyzed by transcript-based microarrays (van den Boom et al., 
2003; Phillips et al., 2006; Rickman et al., 2001). However, recent research shed light on 
the importance of post-transcriptional modifications of mRNAs that alter gene expression 
under physiological conditions, but also gives rise to the pathology of gliomas.  
The main goal of the present study was to investigate CPEB expression in human glioma 
specimens. CPEBs are auxiliary regulators associating with consensus sequences present in 
3’UTRs of mRNAs, which activate or repress their translation. Via this mechanism CPEBs 
regulate essential cellular processes, such as development (Groisman et al., 2002; Novoa et 
al., 2010), memories formation (Theis et al., 2003) and progression of cancer (Ortiz-
Zapater et al., 2012). In the current work aberrant CPEB expression was found to be a 
frequent phenomenon in both, low- and high-grade gliomas. Decreased CPEB1 expression 
was associated with the rising grade of tumor malignancy, suggesting it being a putative 
tumor suppressor. One of the mechanisms potentially underlying transcriptional silencing 
of cancer-related genes might be DNA methylation. However, despite hypermethylation of 
the CPEB1 gene, DNA methylation proved not to be directly responsible for its 
downregulation in gliomas. Thus, the underlying mechanism remains elusive. Abundant 
expression of CPEB 2-4 was detected in numerous human glioma specimens. CPEB2 
expression in endothelial tumor cells suggested that CPEB2-mediated protein synthesis 
takes place in the close proximity of blood vessels within tumor tissue. On the other hand, 
CPEB4 expression appeared to support tumorigenic properties by its putative entanglement 
into local protein synthesis in transformed cells. Intriguingly, only CPEB3 expression was 
correlated positively with tumor progression. Phosphorylation of CPEB3 within the 
alternatively spliced region was negatively correlated with tumor malignancy. The loss of 
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CPEB3 activity in high-grade gliomas is likely caused by the expression of alternatively 
spliced variants. This suggests that a substantial part of the CPEB3 in GBM specimens does 
not undergo phosphorylation and indicates phosphorylation to be a biologically important 
mechanism regulating CPEB3 activity. Furthermore, a significant correlation between 
CPEB3 activity and survival was observed in less aggressive low-grade astrocytomas 
considered to be sGBM precursors. Consequently, CPEB3 may be considered as an 
attractive therapeutic target in gliomas. 
To further investigate the relationship between CPEB activity, growth properties and 
cancer-relevant parameters an in vitro overexpression study was performed. This revealed a 
striking link between CPEB1, enhanced apoptotic activity and enhanced migration. One 
explanation could be that through rapid changes in the cytoskeleton of migrating cell the 
chance of mistakes rises, turning GBM cells towards an apoptotic pathway. On the other 
hand, CPEB2 overexpression decreased apoptotic activity, enhanced migration and by this 
additionally strengthened the cancerous properties of the cells. Importantly, CPEBs were 
also found to regulate various cancer pathways, including the TGF-β signaling cascade. 
However, further studies are needed to fully understand the interaction between CPEBs 
translational control and the pathophysiology of cultured GMB cells and human gliomas.  
Finally, the study revealed that CPEB2 is expressed in different cellular populations, brain 
regions, and stages of development, which indicates that this protein plays an important 
role in regulation of local protein synthesis, synaptic plasticity, and neuronal 
morphogenesis. 
The present study does not only increase our understanding of the function of CPEBs but 
also shows the importance of post-transcriptional modifications of mRNAs as a 
pathophysiological mechanism in gliomas and potentially other cancers. Therefore, these 
results may serve as a valuable basis for the identification of new therapeutic and diagnostic 
factors in cancer treatment. 
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8 PERSPECTIVE 
 
Aberrant expression of CPEBs in human gliomas indicates the importance of post-
transcriptional regulation in cancer cells. However, to fully understand the role of CPEBs in 
this relatively young research filed further investigations are required.  
As increasing evidence confirms the implication of CPEBs in multiple pathological 
processes, most likely CPEB-dependent translation is a more general event in 
tumorigenesis. Therefore, particular attention should be paid to metastatic brain tumors, 
namely cancers beginning in lungs, breast, melanoma, colon, and kidney, and subsequently 
invade the brain. Further investigations of CPEB expression in different kinds of cancer 
may be performed by tissue microarrays or meta-analysis.  
Knowing that CPEBs control the translation of various genes, the identification of target 
transcripts should be a major future task to understand their role in the complex tumor 
environment. Experiments with the objective of identifying mRNAs bound by CPEBs in 
normal versus cancer cells might involve RNA immunoprecipitation followed by DNA 
chip microarray analysis. As an alternative method, crosslinking and immunoprecipitation 
of RNA binding proteins followed by cloning and deep sequencing of the attached RNAs 
might be used. 
Having in mind that solely CPEB splice variants containing the B-region may undergo 
activation, the variants lacking B-region may arrest cytoplasmic polyadenylation and 
translation of bound mRNAs. Therefore, it ought to be examined which mRNAs are 
silenced with the help of this mechanism. The answer may be provided by evaluation of the 
elongation of poly(A) tails of bound mRNAs in normal and cancer cells. Polyadenylation 
may be investigated by a whole-transcriptome approach, such as deep sequencing of 
mRNAs with poly(A) tails.  
Finally, it ought to be considered whether CPEBs might be involved in therapy. For this 
purpose, a straightforward approach of animal models might be used. Xenografts or 
Perspective 
 
136 
 
syngeneic animal models reflecting conditions observed in human GBMs might be valuable 
for personalized therapy of brain tumor patients. This might be particularly important for 
patients who suffered a relapse or whose tumor continues to grow after standard treatment. 
Moreover, this might be the key to test CPEB function in vivo and to translate the latest 
findings on the molecular causes of brain tumors, their risk valuation and new therapeutic 
methods into innovative treatment concepts. 
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